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The oxidation of long chain fatty acids facilitates mitochondrial respiration in 
diverse cell types.  In this thesis, the role of fatty acid oxidation primarily in the adipose 
tissue and liver are discussed. To address this question, we generated mice with an 
adipose- or liver-specific knockout of carnitine palmitoyltransferase 2 (Cpt2), an obligate 
step in long chain mitochondrial fatty acid oxidation. In adipocyte-specific KO mice 
(Cpt2A-/-), the brown adipose tissue (BAT) of Cpt2A-/- mice was unable to utilize fatty 
acids and therefore caused hypothermia after an acute cold challenge. Surprisingly, 
Cpt2A-/- BAT was also unable to up-regulate thermogenic genes such as Ucp1 and Pgc1a 
in response to agonist-induced stimulation in vivo or ex vivo. The adipose specific loss of 
CPT2 did not result in changes in body weight on low or high fat diets, although 
paradoxically, low fat diets promoted and high fat diets suppressed adiposity. 
Additionally, a high fat diet increased oxidative stress and inflammation in gonadal white 
adipose tissue (WAT) of control mice but this effect was greatly suppressed in Cpt2A-/- 
mice. However, this suppression did not improve high fat diet induced glucose 
intolerance. In hepatocyte-specific KO (Cpt2L-/-) mice, fasting induced hepatic steatosis 
and serum dyslipidemia with an absence of circulating ketones while blood glucose 
remained normal. Systemic energy homeostasis was largely maintained in fasting Cpt2L-/- 
mice by adaptations in hepatic and systemic oxidative gene expression mediated in part 
by Pparα target genes including procatabolic hepatokines Fgf21, Gdf15 and Igfbp1. 
However, feeding a ketogenic diet to Cpt2L-/- mice resulted in severe hepatomegaly, liver 
damage and death with a complete absence of adipose triglyceride stores. These results 
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provided the first functional and physiological characterizations of Cpt2 and established 
its importance in energy homeostasis. 
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TISSUE SPECIFIC ROLES OF  
FATTY ACID OXIDATION 
 
 
CHAPTER 1. Overview 
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Dysregulated fatty acid metabolism is strongly linked to the development and 
progression of obesity, diabetes, fatty liver and cardiovascular disease. In particular, 
obesity results when caloric intake exceeds expenditure, directing metabolic flux into 
storing energy, primarily as triglyceride in adipose tissue. Conversely, when caloric 
expenditure exceeds intake, these reserves are mobilized to provide physiological fuel for 
other tissues. To alter body weight, in particular adiposity, either energy intake or 
expenditure or both must be altered.  Energy intake can be managed either behaviorally 
or via bariatric surgery to physically constrain intake.  One popular notion is that 
increasing energy expenditure would be sufficient to decrease adiposity and improve 
glycemic control (1-12).  Indeed, in the early 1900s, chemical uncoupling agents such as 
2,4 Dinitrophenol were used effectively in humans to reduce adiposity (13).  It was 
eventually rendered impractical and banned in 1938 due to a high incidence of mortality 
which is unfortunately still seen today as weight loss enthusiasts purchase it over the 
internet (14).   
More recently, there has been great interest in harnessing the capacity of brown 
and beige adipocytes to rapidly oxidize fatty acids via natural uncoupling as a 
bioenergetic means of “burning fat” and reducing adiposity (1-12).  This idea has gained 
further momentum since the rediscovery of active brown and beige adipocytes in adult 
humans (15-18).  In fact, the entire field of metabolic biochemistry and physiology seems 
to have pivoted towards this idea.  Mouse models that are resistant to high fat diet 
induced weight gain are often mechanistically explained based on a change in energy 
expenditure via increased adipocyte fatty acid oxidation (19-24).  However, it has never 
been directly demonstrated that the suppression or enhancement of fatty acid oxidation in 
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adipocytes leads to changes in adiposity or insulin sensitivity.  In fact, the idea that body 
weight can be suppressed by increasing oxidative capacity in the absence of uncoupling 
has recently been challenged (25-27).  
Mitochondrial long chain fatty acid oxidation is governed by the regulated 
translocation of activated fatty acids (acyl-CoAs) from the cytoplasm to the matrix of the 
mitochondria (Figure 1-1).  This is mediated by successive carnitine acyltransferases.  
CPT1 isoenzymes mediate acyl transfer from long chain acyl-CoAs to carnitine.  
Acylcarnitines can then traverse organic cation transporters in the mitochondrial 
membranes and enter the mitochondrial matrix.  Within the mitochondrial matrix, CPT2 
transfers the acyl group from the acylcarnitine back onto CoA.  The acyl-CoA is then 
used by the beta-oxidation machinery in the matrix.  CPT1 isoenzymes are highly 
allosterically regulated by malonyl-CoA, the rate setting metabolite in de novo fatty acid 
synthesis.  This provides the metabolic logic whereby synthesis and oxidation do not 
occur simultaneously.  
The significance of fatty acid oxidation in many biological processes is made 
evident from multiple mutations in this pathway that cause human disease (28).  For 
example, hypomorphic mutations in CPT2 result in metabolic disease (OMIM #s, 255110 
adult onset, 600649 infantile, and 600650 infantile lethal).  The most severe form 
presents as hypothermia, cardiomegaly, hepatomegaly and hypoglycemia in the first days 
of life presumably from the important roles of fatty acid beta-oxidation in brown 
adipocytes, heart and liver respectively.  Additionally, hypomorphic mutations in CPT1a 
result in hypoketotic hypoglycemia (OMIM # 255120) and a loss of CPT1a or CPT1b in 




Figure 1-1. Diagram of fatty acid oxidation 
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however, it is not apparent from these studies what the cell autonomous role for fatty acid 
oxidation is in vivo. Many laboratories around the world have suggested that the 
oxidation of fatty acids in adipose tissue is an important component for weight gain, 
adiposity and glucose tolerance (1-12, 31-34). Therefore, to test this hypothesis and 
determine the cell autonomous role of fatty acid oxidation in vivo, we have generated a 
mouse model that targets CPT2 specifically in the adipose tissue and liver to determine 
the effect of loss of fatty acid oxidation in these tissues. 
Fatty acid oxidation: Brown adipocytes.   
Brown adipose tissue is essential for heat generation during cold exposure in 
perinatal and adult mammals (1, 26, 35).  Brown adipocytes mediate heat generation by 
uncoupling mitochondrial respiration from ATP generation via an uncoupling protein, 
UCP1, which dissipates the chemiosmotic gradient.  Therefore, protons are diverted from 
the ATP Synthase.  The chemiosmotic gradient forms when reducing equivalents (NADH, 
FADH2) donate electrons to the electron transport chain.  The loss of UCP1 results in 
cold intolerant mice (36) however, the role of UCP1 in obesity remains controversial (26). 
The requirement of fatty acid oxidation during cold thermogenesis is exemplified by cold 
intolerant phenotypes of whole body knockout mouse models of the acyl-CoA 
dehydrogenase enzymes (37-40).  Therefore, fatty acid oxidation is critical for brown 
adipocyte function.   
Fatty acid oxidation: White adipocytes.  
WAT is a remarkably dynamic organ that can dramatically expand and contract in 
triglyceride content depending on the metabolic state of the individual.  It is an insulin 
responsive tissue that can greatly influence insulin resistance (41-43).  In lean humans, 
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~5% of resting metabolic rate can be attributed to white adipocytes.  In obese individuals, 
where >50% of total body weight can be from adipose, this value can double (44).  
Oxygen consumption in white adipose tissue goes down with age and is negatively 
correlated with human obesity (45, 46).  Many genetic forms of obesity in rodents are 
accompanied by suppressed WAT oxidation (19-23).  Furthermore, monozygotic twins 
discordant for obesity showed ~2 fold difference in mitochondrial content in WAT (47).  
Although the oxidation of fatty acids in the fed state is low, fasting doubles the rate of 
white adipocyte fatty acid oxidation and is presumably the major fuel in insulin 
suppressed states (48).  This has led to the hypothesis that mitochondrial dysfunction and 
suppressed fatty acid oxidation in WAT is a contributor to increasing adiposity and 
impaired glucose tolerance (22, 31, 32, 49-52).   
Fatty acid oxidation: Liver.  
Lipid metabolism is also a critical component in the development of fatty liver 
disease (FLD) that could progress on to hepatic steatosis or cirrhosis. Energy combustion 
in the liver is primarily regulated via the peroxisome proliferator-activated receptor 
(PPAR)-alpha dependent fatty acid oxidation in mitochondria and peroxisomes. 
Disrupted lipid metabolism or ineffective PPARα in the liver have been shown to 
increase triglyceride storage in hepatocytes and initiate a series of events that lead to FLD 
(53). In fact, many studies have suggested that FLD begins when energy consumption 
exceeds PPARα-mediated energy expenditure through fatty acid oxidation in the liver. 
When the hepatocytes become apoptotic, they rupture and release triglycerides and long 
chain fatty acids that cause liver injury. Therefore the balance between fatty acid 
synthesis and fatty acid oxidation is crucial to prevent the development of FLD (54-59). 
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The liver is also crucial when the body goes under prolonged fasting. Starvation 
initiates a series of metabolic adaptations to enable continuous production and delivery of 
nutrients to critical organs, tissues and cells (53).  The liver responds to starvation by 
liberating glucose to the circulation initially from glycogen stores followed by de novo 
glucose production (i.e. gluconeogenesis). Fatty acid oxidation is critical for as it 
provides the carbon substrate for ketone production (acetyl-CoA) and mitochondrial 
bioenergetics (ATP, NADH) to facilitate gluconeogenesis.  Therefore, humans with 
disparate inborn errors in mitochondrial fatty acid oxidation exhibit life-threatening 
hypoketotic-hypoglycemia following a fast (54). The liver is thought to dominate fasting 
gluconeogenesis with minor contributions from the kidney and gut.  
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FATTY ACID OXIDATION 
 
 
CHAPTER 2. Adipose fatty acid oxidation is required for 




Ingestion of a calorically dense diet, generally high in fat content, coupled with 
inactivity leads to increased adiposity and eventual obesity. Obesity in turn is highly 
correlated with the development of type 2 diabetes, the metabolic syndrome, and 
cardiovascular disease, among others. The molecular mechanisms by which high-fat diets 
contribute to these pathologies are not well understood, but several themes have emerged. 
Implicated in the etiology and progression of obesity-related pathologies is oxidative 
stress, endoplasmic reticulum stress, and inflammation originating locally at adipose 
depots but acting systemically to promote insulin resistance (48, 62-64). Reversing or 
preventing local adipose tissue inflammation may have beneficial systemic effects against 
insulin resistance. Alternatively, strategies to reverse obesity by increasing adipose 
energy expenditure have been suggested to improve systemic obesity-related 
complications (1). 
Adult mammals have at least two functionally distinct adipose lineages: 
unilocular white adipocytes, which function mainly to store fat, and multilocular brown 
adipocytes, which function mainly to burn fat for thermogenesis. Dysfunctional white 
adipose tissue (WAT) and brown adipose tissue (BAT) have been implicated in the 
pathogenesis of obesity and diabetes. BAT is densely packed with mitochondria and 
requires fatty acid oxidation to fuel heat generation (27, 35-38). Although the oxidation 
of fatty acids in WAT in the fed state is relatively low, fasting doubles the rate of white 
adipocyte fatty acid oxidation and is presumably a major fuel in insulin suppressed states 
(46). Changing macronutrient metabolism specifically in adipocytes can lead to changes 
in adiposity, body weight, and glucose tolerance (22, 39, 65, 66). However, the 
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autonomous contribution of adipose fatty acid oxidation to obesity and insulin resistance 
remains unknown. 
Mitochondrial long-chain fatty acid β-oxidation requires successive carnitine 
acyltransferases to translocate acyl-coenzyme As (acyl-CoAs) from the cytoplasm into 
the mitochondrial matrix (67). The initial and rate-setting enzyme, CPT1, generates 
acylcarnitines that can traverse the mitochondrial membranes via specific transporters. 
CPT1 is allosterically inhibited by the rate-determining metabolite in de novo fatty acid 
synthesis, malonyl-CoA; therefore, the balance of fatty acid synthesis and oxidation is 
metabolically coordinated posttranslationally. Once inside the mitochondrial matrix, 
CPT2 generates acyl-CoAs from acylcarnitines to initiate the b-oxidation of long-chain 
fatty acids to acetyl-CoA. Fatty acids contain an abundant energy potential, making them 
ideal for storage during energy surplus and mobilization during energy deficits. Fatty acid 
oxidation efficiently generates energy but can also promote the generation of reactive 
oxygen species (ROS). ROS can potentiate oxidative stress and inflammation, which can 
impair insulin sensitivity (68). 
Although it is clear that fatty acid oxidation is a critical and fundamental 
metabolic endpoint in humans (26) and rodents (27, 28), it is not clear how adipocyte 
fatty acid oxidation affects whole-body metabolism in an autonomous manner. Therefore, 
we generated a conditional loss-of-function allele for CPT2, an obligate step in 
mitochondrial long-chain fatty acid β-oxidation that is encoded by a single gene. Here we 
show that adipose tissue fatty acid oxidation is required not only for acute cold adaptation 
but also for the induction of thermogenic genes in BAT. The loss of adipose fatty acid 
oxidation altered adiposity in a diet-dependent manner but did not lead to diet-induced 
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changes in body weight. Furthermore, we show that in WAT, the loss of fatty acid 
oxidation reduces high-fat-induced oxidative stress and inflammation but does not alter 
the progression of obesity or glucose intolerance. 
Experimental Procedures 
Animals and Diets 
CPT2lox/lox mice were generated by targeting loxP sequences to introns flanking exon 4 of 
the mouse Cpt2 gene by homologous recombination in C57Bl/6 embryonic stem cells by 
standard methods. To produce mice with a loss of CPT2 specifically in adipocytes, we 
bred CPT2lox/lox mice to adiponectin-Cre transgenic mice (69). CPT2A-/- and littermate 
CPT2lox/lox mice were housed in a facility with ventilated racks on a 14 hr light/10 hr dark 
cycle with access to a standard chow diet (Etruded Global Rodent Diet, Harlan 
Laboratories). For the diet study, mice were fed a 10% low fat (D12450J, Research Diets) 
or a 60% high fat diet (D12492, Research Diets) from 6 weeks to 18 weeks of age (12 
weeks on diet). At week 10 of the diet, mice were subjected to a glucose tolerance test by 
intraperitoneal injection of glucose (0.75 g/kg) and measuring tail blood glucose at 0, 15, 
30, 60, and 120 min. At week 11 of the diet, insulin tolerance tests were performed via 
intraperitoneal injection of insulin (0.6 U/kg) and measuring tail blood glucose at 0, 15, 
30, 60, and 90 min (Nova Max Plus). Body weights were measured on a weekly basis. 
For thermogenesis experiments, 12-week-old mice had food withdrawn for 4 hr and 
placed in a 4°C environment for 3 hr. Body temperature was measured hourly by a rectal 
probe thermometer (BAT-12, Physitemp). BAT, iWAT, gWAT, liver, and muscle were 
collected and frozen in liquid nitrogen. Serum was collected from all mice, and free 
glycerol and TAG (Sigma), b-hydroxybutyrate (StanBio), total cholesterol (Wako), and 
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NEFA (Wako) were measured colorimetrically. BAT collected from thermogenesis 
experiments was homogenized in Media I (10mMTris [pH 8.0], 1mMEDTA, and 0.25M 
sucrose) to measure TAG (Sigma). For in vivo studies, 20-week-old CPT2A-/- and 
littermate CPT2lox/lox mice were injected with CL-316243 (10 mg/kg, Santa Cruz) or 
vehicle. To determine the protein expression of phospho-CREB, CREB, phospho-mTOR 
and mTOR, CL-316243 (10 mg/kg) or vehicle was injected to 20-week old mice and 
tissues were collected after 30min. For cold acclimation, 12–14 week old CPT2A-/- and 
littermate CPT2lox/lox mice were housed in an animal incubator at 18°C on a 12 hr light/12 
hr dark cycle with access to a standard chow diet for one week. The incubator was 
lowered to 15°C the following week. Then mice had food withdrawn for 4 hr and placed 
in a 4°C environment for 4 hr. For thermoneutral adaptation, 12-week-old CPT2A-/- and 
littermate CPT2lox/lox mice were housed in an animal incubator at 30°C on a 12 hr light/12 
hr dark cycle with access to a standard chow diet for 2 weeks. At 14 weeks of age, the 
mice were injected with either CL-316243 (10 mg/kg) or vehicle for 3 hr. All procedures 
were performed in accordance with the NIH’s Guide for the Care and Use of Laboratory 
Animals and under the approval of the Johns Hopkins Medical School Animal Care and 
Use Committee. 
Body Composition and Metabolic Analysis 
Body fat and lean mass were determined by magnetic resonance imaging (minispec 
MQ10) in 18-week-old mice. To measure whole-animal energy utilization, 12-week-old 
male CPT2A-/- and CPT2lox/lox littermates that were fed a standard chow diet were 
individually housed in Comprehensive Laboratory Animal Monitoring System 
(Columbus Instruments) cages on a 12 hr light/12 hr dark cycle. O2 and CO2 consumption 
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and production, respectively, food and water intake, and home-cage activity were 
measured continuously. After a 2-day acclimation period, data were collected for 48 hr 
for ad libitum and a 24 hr fasting period. At the end of the study, the same mice were 
injected with CL-316243 (10 mg/kg) and were monitored for 3 hr. 
In Vivo Acetate Incorporation Experiment 
Six-week-old CPT2A-/- and CPT2lox/lox littermates were fed a 10% low-fat diet for 2 
weeks. At 8 weeks of age, mice were injected with 10 mCi of [3H] acetate for 3 hr. BAT, 
gWAT, and liver were collected, and lipid was extracted using the Folch method. 
Aliquots of the samples were counted for [3H] labeled lipids. All samples were counted 
using the Beckman Coulter scintillation counter (LS 6000SC, Beckman Coulter). 
Cell Culture 
CPT2lox/lox primary MEFs were derived from embryos and cultured in Dulbecco’s 
modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum (FBS) 
and 1% penicillin/streptomycin. To generate CPT2lox/lox and CPT2KO MEFs, cells 
were first transduced with large T antigen-expressing lentiviral particles (LVP016-Neo, 
GenTarget) for 48 hr and G418 (300 mg/mL) was added to select for positive cells. The 
selected cells were then transduced with red fluorescent protein (LVP023, GenTarget) or 
CRE-2A-RFP (LVP013, GenTarget) lentiviral particles and selected with blasticidin (10 
mg/mL) to generate CPT2lox/lox and CPT2KO MEFs, respectively. MEFs were plated in 
T25 flasks at 70% confluency and incubated in DMEM supplemented with 10% FBS and 
1% penicillin/streptomycin overnight. The cells were washed with PBS and the reaction 
mixture for [U-14C] glucose (DMEM [A14430-01], 2 mM glutamine, 2.5 mM glucose, 
0.5 mM sodium pyruvate, 0.1 mCi of [U-14C] glucose) or [2-14C] pyruvate (DMEM 
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[A14430-01], 2mM glutamine, 2.5 mM glucose, 0.5 mM sodium pyruvate, 0.1 mCi of [2-
14C] pyruvate) was added to cells. The flasks were sealed with a rubber stopper 
containing a hanging well filled with filter paper and incubated in a 37°C incubator for 4 
hr. Carbon dioxide was trapped by adding 150 ml of 1 M NaOH to the filter paper in the 
center well and 200 ml of 1 M perchloric acid to the reaction mixture. Then the samples 
were incubated at 55°C for 1 hr and the filter paper was placed in scintillation fluid and 
counted. For [1-14C] oleate oxidation, the reaction mixture (DMEM supplemented with 
0.1 mCi of [1-14C] oleate, 100 mM L-carnitine hydrochloride [Sigma], and 0.2% BSA) or 
the reaction mixture containing 100 mM etomoxir was added to cells and incubated in a 
37_C incubator for 4 hr. Carbon dioxide was collected and counted as described above. 
For [1-14C] lignoceric acid oxidation, the reaction mixture (DMEM supplemented with 
0.1 mCi of [1-14C] lignocerate and 0.2% BSA) was added to cells and incubated 
overnight in a 37°C incubator. Carbon dioxide was collected and counted as described 
above. For substrate flux into lipids, MEFs were plated in 24-well plates and incubated in 
DMEM supplemented with 10% FBS and 1% penicillin/streptomycin overnight and 
washed with PBS the next day. The cells were incubated in [2-14C] pyruvate (DMEM 
[A14430-01], 2 mM glutamine, 2.5 mM glucose, 0.5 mM sodium pyruvate, 0.1 mCi of 
[2-14C] pyruvate) or [3H] acetate (DMEM supplemented with 0.3 mCi [3H] acetate) 
reaction mixture and incubated at 37°C for 4 hr. Lipid was extracted using the Folch 
method, and aliquots of the samples were counted for [3H]-labeled lipids. 
Adipose Tissue Oxidation Experiments 
BAT, iWAT, and gWAT were collected from 20-week-old CPT2A-/- and littermate 
CPT2lox/lox male mice and placed in an incubation chamber containing the reaction 
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mixture (DMEM supplemented with 0.1 mCi of [1-14C] oleate, 100 mM L-carnitine 
(Sigma), and 0.2% BSA). The chamber contained a center well filled with filter paper 
and sealed with a rubber stopper. The incubation chambers were in a 37°C shaking water 
bath for 4 hr. Trapping carbon dioxide was collected as described above. In vivo fatty 
acid oxidation was carried out as previously described (70, 71). 
BAT Explant Experiments 
BAT was collected from 20-week-old mice. Each BAT nugget was cut in half and placed 
in media (DMEM, 10% FBS, 200 mM total of palmitate and oleate at a 1:2 molar ratio, 
BSA at a 1:3 molar ratio with total fatty acids). Forskolin (10 mM, Sigma), isoproterenol 
(10 mM, Sigma), or CL-316243 (10 mM, Santa Cruz) was added to tubes and incubated 
in a 37°C water bath for 3 hr. The tissues were frozen in liquid nitrogen for further 
analysis. 
Analysis of Gene Expression and Mitochondrial DNA by Quantitative PCR 
Total RNA was isolated using the RNeasy Mini Kit (QIAGEN). A total of 1–2 mg of 
RNA was reverse transcribed using the High Capacity cDNA Reverse Transcription Kit 
(Applied Biosciences). The cDNA was diluted to 2 ng/mL and was amplified by specific 
primers in a 20 ml reaction using SsoAdvanced SYBR Green Supermix (Bio-Rad). WAT 
cDNA from CPT2A-/- and littermate CPT2lox/lox mice on a high-fat diet was prepared 
according to the manufacturer’s protocol for the mouse oxidative stress PCR array (SA 
Biosciences). Analysis of gene expression was carried out in a CFX Connect Real-Time 
System (Bio-Rad). For each gene, mRNA expression was calculated as 2^deltaCT 
relative to cyclophilin A expression. For mitochondrial DNA analysis, total DNA was 
prepared using the QIAmp DNA mini Kit (QIAGEN). Mitochondrial DNA was amplified 
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using primers Co1 and Nd1 and was normalized to genomic DNA by primers amplifying 
H19 from genomic DNA as previously described (72).  
Western Blot Analysis 
BAT collected after acute CL-316243 or vehicle injection was homogenized in RIPA 
buffer with protease inhibitors (Complete Mini, Roche) and phosphatase inhibitors 
(PhosSTOP, Roche). All other tissues from the diet study were homogenized in 13 RIPA 
buffer with protease inhibitors (Complete Mini, Roche). BAT, gWAT, iWAT, and liver 
samples from thermogenesis experiments were homogenized in Media I with protease 
inhibitors. All samples were spun down at 10,000 rpm for 20 min, and supernatant was 
collected and assayed by the Pierce BCA Protein Assay Kit (Thermo Scientific) to 
determine the concentration of protein. A total of 30 mg of protein was subjected to SDS-
PAGE and transferred to a nitrocellulose membrane (Protran BA 83, Whatman). The 
blots were probed with the following antibodies: Uqcrc2 (mitoprofile Total OXPHOS, 
Abcam), Sdhb (mitoprofile Total OXPHOS, Abcam), Acsf3 (Pierce), phospho-CREB 
(Ser-133, Millipore), CREB (Pierce), phospho-mTOR (Cell Signaling), and mTOR (Cell 
Signaling) using the appropriate secondary antibodies conjugated to horseradish 
peroxidase. Fasn (BD Biosciences), Aco2 (Cell Signaling), Mcad (GeneTex), Hsc70 
(Santa Cruz), Sod2, and Hadha (GeneTex) used the appropriate Cy5 (Life Technologies) 
or Cy3 (Life Technologies) fluorescent secondary antibodies.  
Oxidative Damage 
Thiobarbituric acid reactive substances (TBARS) were determined in gWAT, and serum 
from 20-week-old male CPT2A-/- and littermate CPT2lox/lox mice fed a high- or low-fat 
diet. WAT was prepared by homogenizing 100 mg of tissue in 500 ml of 13 RIPA buffer 
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with protease inhibitors (Complete Mini, Roche). Homogenates were centrifuged at 1,600 
3 g for 10 min, and 25 ml of supernatant was used to determine oxidative damage via the 
TBARS Assay Kit (Cayman Chemical Company). 
Acylcarnitine Analysis 
iWAT from CPT2A-/- and littermate CPT2lox/lox mice were collected and frozen in liquid 
nitrogen. Approximately 100 mg of tissue was analyzed for acylcarnitine content at the 
University of Michigan Metabolomics Core Services. 
Statistical Analysis 
When only two genotypes were analyzed, statistical significance was determined using a 
student’s t test. Two-way ANOVA was utilized for repeated measures such as body 
temperature over time, weight gain over time, GTT, and insulin tolerance test. 
Significance was determined for p values < 0.05. 
Results 
Generation of Mice with an Adipose Tissue-Specific Deletion of CPT2  
Mitochondrial long-chain fatty acid oxidation requires sequential carnitine 
acyltransferases to translocate acyl-CoAs into the mitochondrial matrix. The regulated 
and rate setting enzyme, CPT1, is encoded by multiple isoenzymes that can functionally 
compensate in some tissues (73). Therefore, to generate a mouse model to assess the 
tissue-specific roles and requirements of fatty acid oxidation, we generated a conditional 
loss-of-function allele for CPT2, an enzyme required in mitochondrial long-chain fatty 
acid b-oxidation that is encoded by a single gene. C57BL/6 embryonic stem cells were 




Figure 2-1. Generation of mice with an adipose-specific KO of CPT2. 
(A) Gene targeting strategy for the Cpt2 gene (Triangles represent lox sites). 
(B) mRNA for Cpt2 in adipose depots and liver of control and Cpt2A-/- mice (n=8). 
(C) Western blot of CPT2 in BAT of control and Cpt2A-/+ and Cpt2A-/- mice. 
(D) Oxidation of 1-14C-oleic acid to 14CO2 in control and Cpt2A-/- adipose depot explants (n=3). 
(E) Oxidation of 1-14C-oleic acid or 1-14C-lignoceric acid to 14CO2 in control and Cpt2 KO MEFs 
(n=3). 
(F) Acylcarnitine profile of iWAT in control and Cpt2A-/- mice (n=8). 
Data are expressed as mean ± SEM. *p<0.05; **p<0.01; N.S., not significant. White bars represent 
control and black bars represent loss of Cpt2. 
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surrounding exon 4 of the Cpt2 gene (Figure 2-1A). Exon 4 encompasses approximately 
one-third of the protein coding sequence including all of the critical catalytic residues 
(74). Loss of exon 4 is predicted to additionally cause a frameshift in the remaining 
exons. To produce mice with a loss of CPT2 specifically in adipocytes, we bred 
CPT2lox/lox mice to adipocyte specific adiponectin-Cre transgenic mice (69). The resulting 
adipose-specific CPT2 knockout (KO) mice, CPT2A-/-, have a loss of Cpt2 mRNA in all 
adipose depots examined (Figure 2-1B). Furthermore, CPT2 protein is substantially 
reduced in BAT of CPT2A-/- mice (Figure 2-1C). As expected, ex vivo gonadal WAT 
(gWAT), inguinal WAT (iWAT), and BAT explants derived from CPT2A-/- mice had a 
greatly suppressed ability to oxidize radiolabeled 1-14C-oleic acid (Figure 2-1D). Long 
chain mitochondrial fatty acid β-oxidation cannot proceed in the absence of CPT2. The 
remaining oxidation of oleic acid in tissues was presumably due to either peroxisomal 
fatty acid oxidation or oxidation in nonparenchymal cells within the adipose depots. To 
test this directly, we derived and immortalized mouse embryonic fibroblasts (MEFs) from 
CPT2lox/lox embryos and infected them with a control or Cre recombinase expressing 
virus. The oxidation of 1-14C-oleic acid in CPT2lox/lox MEFs was severely blunted by 
incubating cells with a large dose (100 mM) of the mitochondrial fatty acid oxidation 
inhibitor etomoxir. The genetic loss of CPT2 in MEFs suppressed oleic acid oxidation to 
the same degree as etomoxir (Figure 1E). However, the oxidation of the very long chain 
lignoceric acid (C24:0), which is oxidized mainly in peroxisomes, was not significantly 
changed (Figure 2-1E). Therefore, the deletion of CPT2 represents an effective strategy 
for inhibiting long chain mitochondrial fatty acid β-oxidation. To determine how the loss 
of CPT2 alters white adipose fatty acid oxidative metabolites, we measured the steady-
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state concentration of carnitine and acyl-carnitine species in iWAT of control and CPT2A-
/- mice. Although CPT2 deficiency results in the inability to utilize long chain acyl-
carnitines and people with CPT2 mutations are diagnosed by the elevation of these 
metabolites in serum, CPT2A-/- mice did not have increased long chain acyl-carnitine 
species in iWAT. Instead, CPT2A-/- iWAT had a strong trend toward suppressed free 
carnitine and acetyl-carnitine and statistically significant reductions in several short chain 
acyl-carnitines (Figure 2-1F). We conclude that long chain acylcarnitines do not build up 
in WAT but are readily transported out of the adipocyte resulting in a tissue specific 
carnitine deficiency due to the inability to properly recycle carnitine in CPT2A-/- WAT. In 
summary, we have generated mice with an adipose-specific defect in mitochondrial long-
chain fatty acid oxidation that is mediated by the loss of an obligate noncompensatory 
step in fatty acid oxidation. 
Adipose Fatty Acid Oxidation Is Required for Cold-Induced Thermogenesis 
BAT is essential for heat generation during an acute cold exposure in perinatal 
and adult mammals (1, 25, 33). The requirement of fatty acid oxidation during cold 
thermogenesis is made evident by cold-intolerant phenotypes of whole-body KO mouse 
models of the acyl-CoA dehydrogenase enzymes (11, 37, 38). To determine the 
autonomous requirement of adipose fatty acid oxidation during adaptive thermogenesis, 
we placed 12-week-old control and CPT2A-/- female mice at 4_C and measured their body 
temperature over 3 hr. Although all of the mice visibly shivered, cold intolerance was 
evident in CPT2A-/- mice, reaching critical hypothermia (30°C) within 3 hr (Figure 2-
2A). The body weights of 12-week-old female CPT2A-/- mice were not different (Figure  
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Figure 2-2. Adipose fatty acid oxidation is required for acute cold-induced thermogenesis. 
(A) Body temperature of control and Cpt2A-/- mice subjected to a 3hr cold challenge (n=10-13). 
(B) Body weights of 12-week-old female control and Cpt2A-/- mice (n=22-26). 
(C) Gross morphology of control and Cpt2A-/- mouse BAT after a 2hr cold exposure. 
(D) Hematoxylin and eosin (H&E)-stained sections of BAT from control and Cpt2A-/- mice at 21°C 
and 3hr at 4°C (Scale bar is 100μM).  
(E) Triglyceride content of BAT of control and Cpt2A-/- mice after a 3hr cold exposure (n=5). 
(F) Serum metabolites of control and Cpt2A-/- mice at 21°C and 3hr at 4°C (n=8). 
Data are expressed as mean ± SEM. *p<0.05; **p<0.01; N.S., not significant. White bars represent 
control and black bars represent loss of Cpt2. 
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2-2B). Upon dissection, CPT2A-/- interscapular BAT was visibly lipid laden, displaying a 
milky appearance in contrast to the dark brown color of control BAT (Figure 2-2C). 
Histologic evaluation demonstrated increased lipid droplet accumulation that did not 
dissipate upon cold stimulation (Figure 2-2D). Consistent with these morphologic 
changes, cold-exposed CPT2A-/- BAT maintained ~3-fold increase in triglyceride content 
compared to BAT from control mice (Figure 2-2E). Evaluation of serum metabolites 
showed normal responses of serum glucose, ketone bodies, and triglycerides to cold 
stimulation in CPT2A-/- mice. However, compared to controls, CPT2A-/- mice had 
increased serum free fatty acids and decreased glycerol during cold stimulation, likely 
due to their inability to utilize the mobilized fatty acids in CPT2 null BAT (Figure 2-2F). 
These data show that adipose fatty acid oxidation is required for acute cold-induced 
thermogenesis.  
BAT Fatty Acid Oxidation Is Required for Agonist-Induced Thermogenic Gene 
Expression 
To understand the transcriptional control of BAT metabolism in CPT2A-/- mice, 
we determined the expression of fatty acid catabolic and anabolic genes. After a 3 hr cold 
stimulation, the fatty acid oxidative genes Acox1, Cpt1b, and Lcad were suppressed in 
CPT2A-/- BAT (Figure 2-3A). Malonyl-CoA decarboxylase (Mlycd), which 
decarboxylates malonyl-CoA and therefore disinhibits CPT1, was greatly suppressed in 
both basal and cold stimulated CPT2A-/- BAT. Additionally, fatty acid biosynthetic genes 
Pcx, Acaca, and Elovl6 were suppressed after a 3 hr cold stimulation in CPT2A-/- BAT 
compared to controls (Figure 2-4A). These data suggest that the loss of fatty acid 





Figure 2-3. Adipose fatty acid oxidation is required for agonist-induced thermogenic gene expression 
and mitochondrial homeostasis. 
(A) mRNA expression of fatty acid oxidative genes in BAT of control and Cpt2A-/- mice at 21°C or 
after 3hr at 4°C. 
(B) mRNA expression of Ucp1, Pgc1α and Dio2 in BAT of control and Cpt2A-/- mice at 21°C (n=8), 
after 3hr at 4°C (n=8) or 3hr after injection with 10mg/kg CL-316243 (n=5). 
(C) mRNA expression of Ucp1 in BAT explants treated with 10μM CL-316243, isoproterenol or 
forskolin (n=5). 
(D) Western blot for PKA phosphorylated substrates in BAT of control and Cpt2A-/- mice treated with 
10mg/kg CL-316243 for 30min in vivo. 
(E) Western blot for phosphorylated-CREB (Ser-133) in BAT of control and Cpt2A-/- mice treated 
with 10mg/kg CL-316243 for 30min in vivo. 
(F) Body temperature of control and Cpt2A-/- mice acclimatized to 15°C and subjected to a 4hr cold 
challenge (n=5). 
(G) mRNA expression of Ucp1, Pgc1α and Dio2 in BAT of 15°C acclimatized control and Cpt2A-/- 
mice after a 4hr cold challenge (n=5). 
(H) mRNA expression of Ucp1, Pgc1α and Dio2 in BAT of control and Cpt2A-/- mice acclimatized to 
30°C and injected with vehicle or 10mg/kg CL-316243 for 3hr (n=4-5). 
(I) Western blot of mitochondrial proteins in BAT of control and Cpt2A-/- mice at 21°C or after 3hr at 
4°C. 
(J) Mitochondrial DNA content of BAT and gWAT from control and Cpt2A-/- mice (n=10-12). 
Data are expressed as mean ± SEM. *p<0.01; **p<0.05. White bars represent control and black bars 





Figure 2-4. Expression of fatty acid metabolic genes in BAT of control and Cpt2A-/- mice. 
(A) mRNA expression of fatty acid biosynthetic genes from BAT of control and Cpt2A-/- mice housed 
at 21°C or after 3hr at 4°C (n=8). Data are expressed as mean ± SEM. *p,0.05. 




the role of fatty acid oxidation on thermogenic programing in BAT, we measured the 
transcriptional response of BAT to cold stimulation. The canonical cold-induced genes 
Ucp1, Pgc1a, and Dio2 were induced robustly in BAT of control mice after 3 hr at 4°C 
but were unresponsive in CPT2A-/- BAT (Figure 2-3B). In fact, Ucp1 and Dio2 were 
suppressed constitutively even at room temperature. Ucp1 and Pgc1a are thermogenic 
genes regulated by adrenergic signaling upon cold exposure. Therefore, we determined if 
CPT2A-/- BAT was responsive to adrenergic stimulation by injecting CPT2A-/- and control 
mice with the selective β3-adrenergic agonist CL-316243 (10 mg/kg) and collected BAT 
3 hr later. Unlike the control, CPT2A-/- BAT elicited no increase in the mRNA abundance 
of Ucp1 or Pgc1a (Figure 2-3B). This suggests a strong defect in CPT2A-/- BAT 
thermogenic gene expression. 
To determine where in the adrenergic signaling pathway CPT2A-/- BAT was 
impaired, we collected control and CPT2A-/- BAT explants and stimulated them ex vivo 
with 10mM CL-316243, the β-adrenergic agonist isoproterenol, or the adenylyl cyclase 
activator forskolin, in the presence of 200mM fatty acids (2:1 oleate: palmitate). All of 
these activators robustly induced Ucp1 in control explants; however, CPT2A-/- BAT was 
unable to induce Ucp1 (Figure 2-3C). These data suggest that the defect in cold-induced 
thermogenic gene expression is mediated downstream of the adrenergic receptor. 
To determine if CPT2A-/- BAT was activating signaling downstream of adrenergic 
stimulation, we probed for protein kinase A (PKA) targets of adrenergic signaling after a 
30 min stimulation with 10 mg/kg CL-316243 in vivo. Utilizing a PKA phosphorylated 
substrate specific antibody, both control and CPT2A-/- BAT showed robust CL-316243 
mediated phosphorylation (Figure 2-3D). Additionally, cAMP response element-binding 
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protein (CREB) phosphorylation, the canonical transcription factor downstream of 
adrenergic stimulation, elicited a robust phosphorylation in both control and CPT2A-/- 
BAT (Figure 2-3E). These data show that CPT2A-/- BAT can activate adrenergic 
signaling and phosphorylation of downstream targets such as CREB. This suggests the 
defect in agonist-induced thermogenic gene expression is likely at the level of 
transcriptional regulation. Taken together, these experiments show that CPT2A-/- BAT is 
resistant to agonist-induced thermogenic gene expression and further suggest that fatty 
acid oxidation in BAT is coupled to agonist-induced transcription. 
CPT2A-/- Mice Are Defective in Environmental Temperature Adaptation 
Mammals can dramatically alter their physiology to adapt to the ambient 
temperature. Cold acclimation of UCP1KO mice is sufficient to rescue their acute cold 
intolerance (75, 76). To test the role of adipose fatty acid oxidation on this adaptation, we 
cold acclimatized CPT2A-/- mice to 15°C and then subjected them to an acute 4°C cold 
challenge. At 15°C, CPT2A-/- and control mice had lower body temperatures (~35.5°C) 
that upon cold challenge initially rose rapidly. However, CPT2A-/- mice could not 
maintain body temperature and after 4 hr reached critical hypothermia (Figure 2-3F). 
Again, Ucp1 and Dio2 mRNA abundance was suppressed in CPT2A-/- BAT (Figure 2-
3G). This suggests that adipose fatty acid oxidation has additional roles other than merely 
activating UCP1 in BAT. Next, we asked if the inhibition of agonist-induced thermogenic 
gene expression at 21°C and 15°C was due to tonic activation of thermogenic signaling 
and therefore constitutively inhibited via negative feedback. To eliminate tonic basal 
thermogenic signaling, we acclimatized CPT2A-/- and control mice to a thermoneutral 
environment (30°C). We then injected the mice with 10 mg/kg CL-316243 or vehicle and 
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collected BAT 3 hr later. Thermoneutral acclimatization did not improve agonist-induced 
thermogenic gene expression in CPT2A-/- mice. In fact, the difference between control 
and CPT2A-/- mice was further exacerbated, suggesting that the transcriptional defect is 
not due to tonic inhibition but is a primary defect (Figure 2-3H). These data show that 
adipose fatty acid oxidation is critical for thermal adaptation.  
Loss of Adipose Fatty Acid Oxidation Disrupts Mitochondrial Homeostasis in BAT 
The lack of agonist-induced Pgc1a expression, a gene key to mitochondrial 
biogenesis, prompted us to examine mitochondrial proteins and mitochondrial density in 
CPT2A-/- BAT. Several mitochondrial proteins were suppressed in CPT2A-/- BAT under 
basal (21°C) conditions, including ACO2 and MCAD (Figures 2-3I and 2-4). These 
changes were exacerbated after 3 hr of cold stimulation. To determine mitochondrial 
number, we quantified BAT mitochondrial DNA and found that gWAT and iWAT 
maintained normal mitochondrial DNA content whereas CPT2A-/- BAT had about a 2-
fold suppression in mitochondrial DNA (Figure 2-3J). These data show that 
mitochondrial long-chain fatty acid oxidation in BAT is important not only for cellular 
bioenergetics but also for nuclear-encoded mitochondrial gene expression, mitochondrial 
protein abundance, and density. 
Bioenergetic Contribution of Adipose Fatty Acid Oxidation 
In the absence of cold stimulation, it was not clear what the contribution of 
adipose fatty acid oxidation is to whole-body energy expenditure under standard 
physiological conditions or perturbations. To determine the physiological contributions of 
adipose fatty acid oxidation, we housed control and CPT2A-/- mice individually in  
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Figure 2-5. Contribution of adipose fatty acid oxidation to energy expenditure. 
(A) VO2 consumption of control and Cpt2A-/- mice treated with 10mg/kg CL-316243. 
(B) Food intake of control and Cpt2A-/- mice. 
(C) Water intake of control and Cpt2A-/- mice under ad libitum and fasting under dark and light cycles. 
(D) Respiratory exchange ratio of control and Cpt2A-/- mice under ad libitum and fasting under dark 
and light cycles. 
(E) Energy expenditure of control and Cpt2A-/- mice under ad libitum and fasting under dark and light 
cycles. 
(F) Ambulation rates of control and Cpt2A-/- mice under ad libitum and fasting under dark and light 
cycles (n=10-14). 
Data are expressed as mean ± SEM. *p<0.05. White bars represent control and black bars represent 




metabolic cages and measured metabolic parameters continuously during ad libitum 
feeding and fasting conditions. Consistent with a requirement for fatty acid oxidation 
during cold exposure, an injection of CL-316243 rapidly increased oxygen consumption 
in control mice but was completely ineffective in altering oxygen consumption in CPT2A-
/- mice (Figure 2-5A). Unlike other models where changes in fatty oxidation drive 
changes in feeding behavior (77), CPT2A-/- mice had no changes in food intake compared 
to control mice (Figure 2-5B). Interestingly, CPT2A-/- mice consumed more water than 
controls during the course of the experiment, particularly during fasting (Figure 2-5C). 
This suggests that adipose tissue fatty acid oxidation may play a role in the generation 
and balance of water, similar to the role of lipid oxidation during hibernation (78). There 
were minor reductions in energy expenditure and increased respiratory exchange ratio in 
CPT2A-/- mice relative to controls (Figures 2-5D and 2-5E). Additionally, there was a 
modest increase in ambulatory activity in CPT2A-/- mice that may reflect a compensatory 
requirement of energy expenditure from skeletal muscle (Figure 2-5F). These data show 
that adipose fatty acid oxidation contributes to overall energy expenditure in the absence 
of cold stimulation, albeit minimally. 
Loss of Adipose Fatty Acid Oxidation Results in Diet-Dependent Changes in Adiposity, 
but Not Body Weight 
It has been suggested that mitochondrial dysfunction and suppressed BAT or 
WAT fatty acid oxidation contributes to changes in body weight and glucose tolerance 
(48, 64). CPT2A-/- BAT is both bioenergetically and transcriptionally unable to support 
thermogenesis. Additionally, we have shown that the oxidation of fatty acids in adipose 
tissue is not a major determinant of whole-animal bioenergetics during ad libitum or 
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fasting conditions. To determine the consequences of a chronic long-term inability to 
oxidize fatty acids in adipocytes on body weight, we placed control and CPT2A-/- mice on 
matched low- and high-fat diets for 12 weeks and measured their body weights weekly. 
CPT2A-/- mice elicited no change in body weight, compared to control littermates, fed 
either a high-fat or low-fat diet (Figure 2-6A). Evaluation of fat and lean content 
revealed a 64% increase in fat mass in low fat-fed CPT2A-/- mice (Figures 2-6B and 2-
6C). Measurement of fat pad weights of low-fat-fed CPT2A-/- mice showed 67% increases 
in both gonadal and inguinal fat pads (Figure 2-6D). 
High-fat-fed CPT2A-/- mice displayed a suppression of fat mass that was mainly 
the result of changes in inguinal adiposity (Figures 2-6C and 2-6D). These seemingly 
paradoxical results are actually consistent with other models with dysfunctional adipose 
fatty acid oxidation or uncoupling (36, 79) and likely reflect compensatory increases in 
energy expenditure in tissues other than adipose. The expression of fatty acid 
biosynthetic genes was largely unchanged between control and CPT2A-/- gWAT; 
however, there were increases in fatty acid oxidative genes Cpt1a and Mlycd in low-fat-
fed CPT2A-/- gWAT (Figure 2-7A). This suggests distinct regulatory mechanisms in 
CPT2A-/- BAT and gWAT, since Cpt1b and Mlycd were decreased in CPT2A-/- BAT. 
Consistent with increased compensatory energy expenditure, high-fat-fed CPT2A-/- mice 
displayed about a 2-fold increase in circulating ketones compared to control high-fat-fed 
mice (Figure 2-6E). 
Analysis of gene expression in iWAT and liver of control and CPT2A-/- mice 
shows that under high-fat conditions, many of the changes between the genotypes were 
concentrated in the iWAT (Figure 2-7B). Conversely, liver from control and CPT2A-/-  
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Figure 2-6. The loss of adipose fatty acid oxidation affects diet-dependent adiposity but not body 
weight. 
(A) Body weights of control and Cpt2A-/- mice fed a low- or high-fat diet (n=13-18). 
(B) H&E stained sections of gWAT from control and Cpt2A-/- mice fed a low- or high-fat diet (Scale 
bar is at 250μM). 
(C) Body compositions measured by EchoMRI for control and Cpt2A-/- mice fed a low- or high-fat diet 
(n=13-18). 
(D) Wet weights of iWAT and gWAT unilateral depots for control and Cpt2A-/- mice fed a low- or 
high-fat diet (n=13-18). 
(E) Serum metabolites in control and Cpt2A-/- mice fed a low- or high-fat diet (n=8). 
Data are expressed as mean ± SEM. **p<0.01; *p<0.05. White bars represent control and black bars 
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Figure 2-7. Expression of thermogenic and fatty acid metabolic genes in gWAT, iWAT and liver of 
control and Cpt2A-/- mice fed a low- or high-fat diet. 
(A) mRNA expression of metabolic genes from gWAT of control and Cpt2A-/- mice fed a low- or high-
fat diet. 
(B) mRNA expression of metabolic genes from iWAT of control and Cpt2A-/- mice fed a low- or high-
fat diet. 
(C) mRNA expression of metabolic genes from liver of control and Cpt2A-/- mice fed a low- or high-
fat diet. 
Data are expressed as mean ± SEM. *p<0.05. 
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mice showed most differences after low-fat feeding (Figure 2-7C). This shows that 
individual tissues and even different adipose depots respond disparately. These data 
demonstrate that the loss of adipose fatty acid oxidation does not contribute to changes in 
total body weight regardless of dietary lipid content, but that CPT2A-/- mice displayed 
differences in adiposity that were diet dependent. 
Loss of Adipose Fatty Acid Oxidation Is Compensated in Part by Altered Carbohydrate 
Metabolism 
The diet-dependent changes in adiposity in CPT2A-/- mice are consistent with 
other cold-intolerant models (36, 79). Nonetheless, we were interested in determining the 
flux of macronutrients in tissues lacking CPT2. First, we directly tested the ability of 
CPT2A-/- mice to fully oxidize radiolabeled 1-14C oleic acid in vivo. Consistent with the 
indirect calorimetry data, we did not observe differences in whole-body fatty acid 
oxidation between control and CPT2A-/- mice (Figure 2-8). 
Next, we determined the rate of de novo fatty acid synthesis by injecting 3H-
acetate to control and CPT2A-/- mice for 3 hr and extracting lipids from liver, gWAT, and 
BAT. Although the livers of control and CPT2A-/- mice had equal incorporation of 3H-
acetate into lipids, both gWAT and BAT had an ~2-fold increase in incorporation 
(Figure 2-9A). This suggested that there was an increase in carbohydrate utilization in 
cells where CPT2 was deleted. Therefore, we assayed 3H-acetate incorporation into lipids 
in control and CPT2KO MEFs. Consistent with the in vivo data, CPT2KO MEFs had a 2-
fold increase in de novo lipogenesis from both 3H-acetate and 2-14C-pyruvate (Figure 2-
9B). Additionally, we examined the oxidation of radiolabeled 2-14Cpyruvate and U-14C-








Figure 2-9. The loss of fatty acid oxidation alters carbohydrate metabolic flux. 
(A) De novo lipogenesis of control and Cpt2A-/- liver, gWAT and BAT from a 1hr injection of 3H-
acetate normalized to tissue wet weight (n=4-5). 
(B) De novo lipogenesis of control and Cpt2A-/- MEFs from 3H-acetate or 2-14C-pyruvate normalized 
to protein concentration (n=6). 
(C) Substrate oxidation of control and Cpt2A-/- MEFs from 2-14C-pyruvate or U-14C-glucose 
normalized to protein concentration (n=5). 
Data are expressed as mean ± SEM. *p<0.05. White bars represent control and black bars represent 
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increased 2-fold over control cells (Figure 2-9C). These data show that the loss of fatty 
acid oxidation is compensated in part by increased carbohydrate flux.  
Adipose Fatty Acid Oxidation Potentiates High-Fat Diet-Induced Oxidative Stress and 
Inflammation 
The oxidation of fatty acids generates a substantial oxidative burden. It has been 
previously demonstrated that high-fat feeding increases oxidative stress and damaging 
oxidative end products particularly within gWAT (80). Given the role of fatty acid 
oxidation in the generation of ROS, we profiled genes known to be involved in oxidative 
stress in high-fat fed control and CPT2A-/- gWAT by quantitative PCR (qPCR) array. 
Multiple genes involved in detoxifying ROS were increased and several more involved in 
generating ROS were suppressed (Figure 2-10). To confirm and extend this data, we 
analyzed the genes and pathways identified in the qPCR screen in gWAT RNA isolated 
from both low- and high-fat-fed control and CPT2A-/- mice. Sod1 and Sod2 trended 
toward an increase under high-fat conditions, and Sod2 was significantly increased ~2-
fold in low-fat-fed CPT2A-/- gWAT. Genes that increase oxidative stress were suppressed 
in CPT2A-/- gWAT specifically in high-fat-fed conditions (Figure 2-11A). Therefore, 
CPT2A-/- gWAT gene expression was consistent with greater ROS detoxification and 
lower ROS generation. This led us to look at the mRNA abundance of adipokines, 
cytokines, and inflammatory markers in gWAT of control and CPT2A-/- mice. Cox2 
mRNA abundance, which produces inflammatory mediators, was robustly suppressed in 
high-fat-fed CPT2A-/- gWAT compared to controls (Figure 2-11A). Adiponectin mRNA 
abundance, which is regulated by redox and suppressed in diabetes, rebounded in high-




Figure 2-10. Expression of oxidative stress genes in gWAT of control and Cpt2A-/- mice fed a high-fat 
diet, related to Figure 2-7. 
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mRNA abundance in gWAT was unchanged between genotypes, Fgf-21 and Adipsin 
were significantly suppressed in low-fat-fed CPT2A-/- mice (Figure 2-11B). 
Since Adipsin, also known as complement factor D, is involved in the 
inflammatory response, we next looked at inflammatory markers in CPT2A-/- gWAT. 
Although, the macrophage marker F4/80 was unchanged between CPT2A-/- and control 
mice, there was a suppression in Cd11b (Mac-1), a marker for activated macrophages, in 
high-fat-fed CPT2A-/- gWAT (Figure 2-11C). Consistent with these changes, there was a 
marked suppression in inflammatory gene expression as evidenced by lower mRNA 
abundance of Mip-1a and Il-1b, as well as a trend for the suppression in Mip1b in high-
fat-fed CPT2A-/- gWAT (Figure 2-11C). 
Additionally, the mRNA abundance of the anti-inflammatory cytokine Il-10 was 
significantly suppressed in high-fat-fed CPT2A-/- gWAT. There were no changes in the 
mRNA abundance of several important inflammatory and insulin-resistance-promoting 
cytokines/chemokines Tnf-a, Il-6, or Mcp1 in control and CPT2A-/- gWAT (Figure 2-
11C). Finally, we measured oxidized lipids in gWAT and serum of low- and high-fat-fed 
control and CPT2A-/- mice. The high-fat diet-induced increase in lipid peroxidation 
observed in control gWAT and serum was repressed in CPT2A-/- mice (Figure 2-11D). 
These data show that high-fat feeding requires mitochondrial oxidation to potentiate 
high-fat diet-induced oxidative stress and inflammation. 
Improvements in CPT2A-/- Adipose Tissue Oxidative Stress Did Not Lead to Improved 
Systemic Glucose Tolerance 
Adipose oxidative stress and inflammation induced by high-fat feeding has been 




Figure 2-11. Adipose fatty acid oxidation potentiates high-fat induced oxidative stress and 
inflammation. 
(A) Quantitative RT-PCR (qRT-PCR) of oxidative stress genes from gWAT of control and Cpt2A-/- 
mice fed a low- or high-fat diet (n=8). 
(B) qRT-PCR of adipokines from gWAT of control and Cpt2A-/- mice fed a low- or high-fat diet (n=8). 
(C) qRT-PCR of inflammatory genes from gWAT of control and Cpt2A-/- mice fed a low- or high-fat 
diet (n=8). 
(D) TBARS assay from gWAT and serum of control and Cpt2A-/- mice fed a low- or high-fat diet 
(n=5). 
(E) Intraperitoneal glucose tolerance test (ipGTT) and intraperitoneal insulin tolerance test (ipITT) 
including area under the curve and area above the curve, respectively, for control and Cpt2A-/- mice 
fed a low fat diet (n=9). 
(F) Intraperitoneal glucose tolerance test (ipGTT) and intraperitoneal insulin tolerance test (ipITT) 
including area under the curve and area above the curve, respectively, for control and Cpt2A-/- mice 
fed a high fat diet (n=13-18). 
Data are expressed as mean ± SEM. **p,0.005; *p<0.05.  
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Figure 2-12. Glucose tolerance of chow fed control and Cpt2A-/- mice, related to Figure 2-7. 
(A) ipGTT for control and Cpt2A-/- mice fed a chow diet. 
(B) Area under the curve for GTT of control and Cpt2A-/- mice fed a chow diet (n=10-14). 
Data are expressed as mean ± SEM. 
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we have greatly suppressed oxidative stress and improved inflammatory markers in 
CPT2A-/- mice fed a high-fat diet, we determined glucose tolerance for control and 
CPT2A-/- mice fed both low- and high-fat diets by glucose and insulin tolerance tests. 
Consistent with an increase in adiposity, low-fat-fed CPT2A-/- mice exhibited greater 
glucose intolerance exhibited by impaired glucose disposal during the glucose tolerance 
test (GTT) and a strong trend toward impaired glucose clearance in response to insulin in 
the ITT (Figure 2-11E). These defects in glucose tolerance are not seen in chow-fed 
mice, suggesting that the high content of simple sugars (i.e., sucrose) promote lipid 
deposition and glucose intolerance in adipose in the absence of fatty acid oxidation 
(Figure 2-12). In contrast, high-fat-fed control and CPT2A-/- mice had similar glucose 
dynamics (Figure 2-11F). Therefore, the improvements in adiposity, oxidative stress, and 
inflammation in high-fat-fed CPT2A-/- mice were not sufficient to reverse systemic insulin 
resistance and glucose intolerance and are not consistent with a requirement for adipose-
derived ROS in mediating systemic glucose intolerance. 
Discussion 
Obesity is the result of energy imbalance. As caloric intake exceeds expenditure, 
metabolic flux is directed into energy reserves, primarily as triglyceride in adipose tissue. 
Conversely, when caloric expenditure exceeds intake, these reserves are mobilized to 
provide physiological fuel. Alterations in adipocyte-specific metabolism can lead to 
systemic changes in adiposity, body weight, and glucose tolerance (39, 50, 65, 66). The 
suppression of adipocyte fatty acid oxidation is often invoked as a mechanism to explain 
mouse models that are obese in the absence of increased food intake. Although this is not 
an implausible idea, it has lacked an experimental underpinning. Contrary to this notion, 
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we have shown that the lack of adipocyte long-chain fatty acid oxidation does not lead to 
changes in body weight under standard laboratory conditions even when challenged by 
calorically dense diets. 
BAT can dramatically increase metabolic rate and dissipate large amounts of 
stored lipids in a relatively short time once activated. Transgenic mice with increased 
BAT mass correlate nicely with resistance to weight gain (24). The transplantation of 
large amounts of BAT into mice improves their glucose tolerance but does little to 
improve their body weight (3). This may point to a robust endocrine rather than 
bioenergetic contribution of BAT. In fact, in the absence of cold-induced activation, the 
role of brown adipocyte bioenergetics in obesity remains controversial (25). Similar to 
CPT2A-/- mice, UCP1KO mice are resistant to, rather than prone to, diet-induced obesity 
at 20°C (79). Aging or a thermoneutral environment can alter this phenotype to produce 
obese-prone UCP1KO mice (81, 82). Additionally, the loss of ACSL1 in adipocytes, 
which renders mice unable to efficiently activate fatty acids for oxidation, leads to an 
increase in adiposity with low fat feeding similar to CPT2A-/- mice (36). Activation of 
catabolic processes in tissue other than adipose, needed to maintain body temperature, 
likely accounts for their lack of body-weight change and altered adiposity (83). These 
experiments illuminate a compensatory role of basal metabolic rate to compensate for the 
loss of BAT mediated thermogenesis; however, little is known about how the basal 
metabolic rate is regulated, where it emanates from, or mechanistically how it contributes 
to body temperature or body weight. 
The phosphorylation of CREB by adrenergic stimulation induces the robust 
expression of thermogenic genes in BAT, including Ucp1 and Pgc1a. Conversely, several 
 44 
nuclear hormone receptors and corepressors such as LXRa and RIP140 negatively 
regulate thermogenic genes (84, 85). LXRa selectively represses Ucp1 induction by 
binding adjacent to CREB on the Ucp1 promoter. The crosstalk between fatty acid 
metabolism and thermogenic programing is likely mediated by fatty acid metabolites 
acting as ligands for nuclear hormone receptors to suppress agonist induced 
transcriptional control. The fact that ACSL1A-/- mice are cold intolerant but still retain 
thermogenic gene induction suggests the defect in CPT2A-/- BAT gene expression lies 
between the activation of fatty acids and their oxidation (36). Similar to CPT2A-/- mice, 
systemic carnitine deficiency also results in a suppression of Ucp1 expression in BAT 
(86). These data suggest that an accumulation of fatty acid metabolites, such as long 
chain acyl-CoAs, for example, may be critical nuclear hormone ligands acting as negative 
metabolic feedback sensors to link metabolic capacity to nuclear encoded mitochondrial 
gene expression. 
Although CPT2A-/- mice were unable to generate heat or oxidize fatty acids in 
BAT and WAT, they did not have changes in body weight when fed standard chow, low-
fat, or high-fat diets. Under low-fat feeding, the mice gained more adiposity, but this was 
likely due to the high sucrose content in the diet, as chow feeding did not elicit increased 
adiposity. Low-fat-fed mice have enhanced de novo fatty acid synthesis in WAT, likely 
in part due to decreased concentrations of cellular L-carnitine and acetylcarnitine. Lower 
L-carnitine and acetylcarnitine levels can shift mitochondria to increased de novo 
lipogenesis by the inability to dissipate mitochondrial acetyl-CoA and thereby its 
allosteric effects on the pyruvate dehydrogenase complex and pyruvate carboxylase (87). 
High-fat feeding elicited a suppression in adiposity in CPT2A-/- mice and a concomitant 
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~2-fold increase in circulating ketones. Severe forms of cold intolerance such as 
ACSL1A-/-, CPT2A-/- mice, and UCP1KO mice are either neutral or mildly resistant to 
high fat diet-induced obesity at room temperature (36, 79). However, mouse models with 
mild cold intolerance are obese prone at room temperature (88, 89). One possible 
explanation for this paradox is that mild BAT dysfunction may evade the reflexive 
compensation required to maintain body temperature, resulting in increased weight gain. 
Long-term housing of mice at thermoneutrality may relieve this compensation and 
generate obese-prone CPT2A-/- mice similar to UCP1KO mice (81). It is not clear, 
however, what the role of uncoupling and heat generation is at thermoneutrality. Is there 
still a need for BAT thermogenesis, or is uncoupling required for something else entirely, 
such as the generation of metabolic water (78, 90)? 
It is clear that fatty acid oxidation is important in BAT; however, how does fatty 
acid oxidation in WAT contribute? The high oxidative stress and inflammation seen after 
long-term high-fat feeding has been attributed to fatty acid metabolism, which we 
confirm here (80). Here, we have evidence that the rate setting step in fatty acid oxidation 
is transcriptionally upregulated 6-fold in high-fat-fed gWAT (Figure 2-7A). We also 
observed increases in oxidative stress and inflammation under a high-fat diet, and these 
changes are greatly reduced in the absence of adipose fatty acid oxidation. Systemic 
glucose intolerance attributed to local adipose dysfunction was not, however, ameliorated 
by the loss of CPT2. We observed a suppression in gWAT inflammation in CPT2A-/- 
mice, as evidenced by a suppression in Cd11b, Cox2, Mip1a, and Il1b. The major and 
likely most relevant inflammatory mediators for insulin resistance such as Tnf-a and 
Mcp1, for example, were unchanged (63). Therefore, these important mediators of 
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obesity-induced insulin resistance were not dependent on adipose mitochondrial long-
chain fatty acid β-oxidation.  
In summary, adipose tissue fatty acid oxidation is critical for acute adaptation to 
the cold by providing both the energy required to fuel heat generation and the 
transcriptional regulation of BAT thermogenesis. Additionally, white adipose fatty acid 
oxidation potentiates high-fat diet-induced oxidative stress and inflammation; however, 
the improvements seen in CPT2A-/- mice were not sufficient to reverse systemic insulin 
resistance. Taken together, adipose fatty acid oxidation is an important metabolic process 
for environmental and nutritional homeostasis. 
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TISSUE SPECIFIC ROLES OF  
FATTY ACID OXIDATION 
 
 
CHAPTER 3. Loss of adipose fatty acid oxidation does not potentiate 




Obesity is driven by energy imbalance. Overconsumption of a calorie-dense diet 
increases energy storage mainly as triglyceride in white adipose tissue (WAT). 
Concomitantly, the inability to use this energy potentiates adiposity and body weight 
gain. Although great strides are being made in understanding the regulation of food 
intake, less is known about the regulation and contribution of energy expenditure to 
obesity. Determining the tissue-specific contribution of macronutrient metabolism to 
energy expenditure is critical for understanding the balance of energy intake and 
expenditure. 
WAT plays an important role in energy storage but contains few mitochondria 
and contributes minimally to organismal bioenergetics in an autonomous manner. 
Alternatively, brown adipose tissue (BAT) is densely packed with mitochondria and can 
rapidly and robustly affect whole animal energy expenditure when deployed during a 
cold challenge (24). The physiological role of BAT is to produce heat to maintain body 
temperature during a cold challenge. This is accomplished via uncoupling cellular 
respiration from ATP generation via the mitochondrial transporter uncoupling protein-1 
(Ucp1). Fatty acid oxidation is critical for this process (35, 38, 91) and provides the 
biophysical activator of uncoupling in BAT (92). Mice with an adipose-specific loss of 
fatty acid oxidation are severely cold intolerant, demonstrating an autonomous 
requirement for adipose fatty acid oxidation in cold-induced thermogenesis (36, 93). 
Because of the large potential to alter energy expenditure, it is tempting to suggest 
that defects in brown or beige adipocytes can lead to an obesogenic phenotype. 
Therefore, it was somewhat surprising that uncoupling protein-1 knockout (Ucp1KO) 
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mice were resistant to rather than prone to diet-induced obesity (34, 79). One caveat is 
that standard laboratory animal housing is below the thermal preference for mice, 
generating a mild cold stress. Mice have a large surface-to-volume ratio and need to 
expend large amounts of energy defending their body temperature against the 
environment. Removing this cold stress by rearing mice at thermoneutrality (30°C) 
acutely reversed this phenotype and generated obesity-prone Ucp1KO mice, revealing a 
strong environmental impact on body weight and energy expenditure (81).  
Recently, we generated mice with a loss of adipose fatty acid oxidation by 
knocking out carnitine palmitoyltransferase 2 (Cpt2), an obligate step in mitochondrial 
long-chain fatty acid β-oxidation (93). Similar to Ucp1KO mice, Cpt2A-/- mice were 
severely cold intolerant, but mildly resistant to high fat diet-induced adiposity. To 
understand the effect of ambient temperature on BAT deficient in fatty acid oxidation, we 
acclimatized Cpt2A-/-mice to thermoneutrality (30°C) and demonstrate a severe loss of 
agonist-induced thermogenic gene induction and loss of interscapular BAT after long-
term housing of Cpt2A-/- mice at thermoneutrality. Surprisingly, given the severity of cold 
intolerance and suppression of molecular and cellular thermogenic programming in 
Cpt2A-/- BAT, thermoneutral housing did not affect diet-induced obesity in Cpt2A-/- mice. 
These data show that bioenergetically and transcriptionally incompetent BAT does not 
potentiate obesity, even at thermoneutrality. 
Experimental Procedures 
Animals 
Cpt2lox/lox and Cpt2A-/- mice and diets were previously described (93). Control mice are 
defined as sex-matched Cpt2lox/lox littermates. For the diet study, Cpt2lox/lox and Cpt2A-/- 
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mice were fed a 60% high-fat diet (D12492, Research Diets) starting at 6 weeks of age 
and continuing for 12 weeks. For temperature acclimation studies, Cpt2lox/lox and Cpt2A-/- 
mice were housed at the indicated temperatures for 2 weeks in an animal incubator (Key 
Scientific) on a 12 hr light/12 hr dark cycle. Serum was collected from all mice to 
measure free glycerol and triacylglycerol (Sigma), β-hydroxybutyrate (Stan-Bio), total 
cholesterol (Wako), and non-esterified fatty acid (Wako). Blood acylcarnitines were 
quantified from dried blood spots (DBSs) with modifications (94, 95). Punched one-
eighth-inch DBS samples were submerged in 100 ml of methanol solution containing 
internal acylcarnitine standards (NSKB, Cambridge Isotopes). Samples were incubated at 
4°C for 20 min and dried under the nitrogen; then 60 ml 3N HCl in n-butanol was added. 
The samples were incubated for 15 min at 65°C and then dried under LN2, and butylated 
acylcarnitines were reconstituted in 100 ml of mobile phase acetonitrile/water/formic acid 
(H2O:CH3CN:HCOOH, 80:19.9:0.1 v/v%). Samples were vortexed, transferred to a 
centrifuge filter, spun, and transferred to injection vial. Acylcarnitines were analyzed on 
an API 3200 (AB Sciex) operated in positive ion mode employing a precursor ion scan 
for m/z 85, which is generated as a characteristic product ion of butyl ester of 
acylcarnitine species. Quantitation of acylcarnitines was achieved by Chemoview (AB 
Sciex) application. Body composition was measured using quantitative nuclear magnetic 
resonance technology (Echo-MRI-100) to determine fat and lean mass. Energy 
expenditure and RER were measured using Oxymax indirect calorimetry cages 
(Columbus Instruments). All procedures were performed in accordance with the NIH’s 
Guide for the Care and Use of Laboratory Animals and under the approval of the Johns 
Hopkins Medical School Animal Care and Use Committee. 
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Analysis of gene expression and mitochondrial DNA. 
Trizol followed by the RNeasy Mini Kit (QIAGEN) was used to obtain total RNA. 
Microarray analysis was done using affymetrix mouse exon arrays (GSE72210). For 
qRT-PCR, 1-2 μg of RNA was reverse transcribed using the High Capacity cDNA 
Reverse Transcription Kit (Applied Biosciences). cDNA was diluted to 2 ng/μL and was 
amplified by specific primers in a 20μL reaction using SsoAdvanced SYBR Green 
Supermix (Bio-Rad). Analysis of gene expression was carried out in a CFX Connect 
Real-Time System (Bio-Rad). For each gene, mRNA expression was calculated as 
2∧deltaCT relative to cyclophilin A expression. For mitochondrial DNA analysis, total 
DNA was prepared using the QIAmp DNA mini Kit (QIAGEN).  
Western Blots 
For western blots, protein was obtained by homogenizing tissues in 1x RIPA buffer (50 
mM Tris-Cl pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 0.25% 
deoxycholate). The concentration of the protein was obtained using the BCA Protein 
Assay Reagent (Pierce, Rockford, IL). 30 μg of protein was used in an SDS-PAGE and 
transferred to either a nitrocellulose (Protran BA 83, Whatman) or a polyvinylidene 
difluoride (PVDF) membrane and blocked with 3% BSA-TBST (tris buffer saline with 
tween 20). The blots were probed with the following antibodies: CPT2 
(Thermoscientific), ACADM (GeneTex), UCP1 (Abcam), Pgc1α (Abcam), ATP5A 
(Abcam), and Hsc70 (Santa Cruz Biotechnology). Cy3 fluorescent antibody was used for 
Hsc70 and the corresponding secondary antibodies conjugated to horseradish peroxidase 
were used for other primary antibodies. 
Statistical Analyses 
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Multiple comparisons were calculated using a two-way ANOVA. Acylcarnitines were 
analyzed using repeated-measures ANOVA with a Bonferroni post hoc correction. 
Pairwise comparisons were calculated using a two-tailed Student’s T-test. Significance 
was determined as: *p<0.05; **p<0.01; ***p<0.001. 
Results 
The loss of adipose fatty acid oxidation results in broad transcriptional dysregulation 
at thermoneutrality.  
Previously, we showed that the loss of an obligate step in mitochondrial long 
chain fatty acid β-oxidation specifically in adipocytes (Cpt2A-/-) resulted in severe cold 
intolerance (93). Cold intolerance was expected given the critical role of fatty acid 
oxidation for providing the mitochondrial bioenergetics as well as biophysical activator 
of uncoupling in BAT (2, 37, 38). Unexpectedly, Cpt2A-/- BAT failed to up-regulate 
thermogenic programming in response to cold, β3-adrenergic agonists or forskolin (93). 
To better understand the role of fatty acid oxidation on the transcriptional control of 
BAT, we acclimatized Cpt2A-/- and littermate control mice to thermoneutrality (30°C) for 
two weeks. Thermoneutrality relieves facultative thermogenesis and reduces the 
requirement for basal tonic adrenergic signaling in BAT. We then injected the mice with 
the selective β3-adrenergic agonist CL-316243 (10mg/kg) or saline and collected 
interscapular BAT 3hrs later and preformed genome wide gene expression profiling on 
BAT mRNA via DNA microarrays (Figure 3-1A,B). Microarray analysis revealed broad 
transcriptional dysregulation upon the loss of fatty acid oxidation particularly in response 
to the β3-adrenergic agonist. 
To validate the microarray results in a larger cohort of mice, we analyzed a subset 
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Figure 3-1. Transcriptional response of Cpt2A-/- BAT to adrenergic stimulation at thermoneutrality. 
(A) Gene expression profiling via microarray of Cpt2, Cpt1b and Acadm at thermoneutrality 3hrs 
after injection with vehicle or CL-316243 injected control and Cpt2 A-/- BAT (n=5). 
(B) Heat map of genes exhibiting statistically significant (p<0.05) changes from microarray analyses 
are shown for vehicle or CL-316243 injected control and Cpt2A-/- BAT (n=3). 
(C) mRNA expression in BAT of thermogenic and brown fat enriched genes (n=5). 
(D) mRNA expression in BAT of Ppar and Ppar target genes (n=5). 
(E) mRNA expression in BAT of metabolic genes (n=5). 
(F) Western blots of BAT from control and Cpt2A-/- mice at thermoneutrality. 
(G) mRNA expression of Cpt2, Ucp1, Pgc1 and Dio2 in BAT of control and Cpt2A-/- mice after 
2wks at 15°C, 22°C and 30°C injected with vehicle of CL-316243 (n=5). 




Figure 3-2. Transcriptional response of control and Cpt2A-/- iWAT to adrenergic stimulation at 
thermoneutrality, related to Figure 3-1. 
(A) Figure Legend. 
(B) mRNA expression in iWAT of thermogenic and brown fat enriched genes (n=5). 
(C) mRNA expression in iWAT of Pparα and Pparα target genes (n=5). 
(D) mRNA expression in iWAT of metabolic genes (n=5). 
Data are expressed as mean ± SEM. *p<0.05; **p<0.01; ***p<0.001. 
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of genes identified in the microarray analysis by qRT-PCR. In agreement with our 
previous studies (93), thermogenic genes Ucp1, Pgc1a, Elovl3, and Dio2 failed to be 
induced upon β3-adrenergic stimulation in vivo (Figure 3-1C). Alternatively, inguinal 
white adipose tissue (iWAT) of Cpt2A-/- mice exhibited significant suppression of Ucp1 
but was still responsive to β3-adrenergic stimulation (Figure 3-2). Other models of BAT 
dysfunction have shown a switch in identity from BAT to WAT (96, 97); however, 
Cpt2A-/- BAT largely maintained its transcriptional identity but again lost β3-adrenergic 
induction (Figure 3-1C). Loss of triglyceride hydrolysis results in defects in β-oxidation 
and a loss of Pparα signaling (65, 98-100). Cpt2A-/- BAT did not exhibit a defect in 
Pparα, and the canonical Pparα target Acot1 was increased at baseline; however, these 
genes were again not induced by the β3-adrenergic agonist (Figure 3-1D). Consistent 
with the metabolic defects induced upon the loss of β-oxidation, Cpt2A-/- BAT exhibited 
defects in β3-adrenergic induction of genes in several metabolic pathways, such as Gyk 
(glycerolipid synthesis), Pdp2, and Pdk4 (pyruvate-tricarboxylic acid cycle flux) (Figure 
3-1E). Alternatively, iWAT remained sensitive to β3-adrenergic stimulation, and Pdp2 
and Pdk4 showed increased expression following CL-316243 injection (Figure 3-2). The 
transcriptional deficits in BAT were mirrored by alterations in the protein abundance for 
Ucp1, Pgc1α, and Acadm (Figure 3-1F). These data show that the loss of fatty acid b-
oxidation via genetic perturbation of Cpt2 results in a defective transcriptional response 
to β3-adrenergic stimulation specifically in BAT.  
The difference between agonist induced thermogenic gene induction between 
control and Cpt2A-/- BAT at 30°C was much larger than we observed at lower ambient 
temperatures (93). To understand if this was due to a change in basal expression or 
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inducibility, we acclimatized control and Cpt2A-/- mice for two weeks to 15°C, 21°C, or 
30°C and then injected them with saline or CL-316243 (10mg/kg) and collected 
interscapular BAT 3hrs later. We then analyzed the expression of Ucp1, Pgc1α, and Dio2 
(Figure 3-1G). Basal Ucp1 expression in WT BAT increased with decreasing 
temperature but was induced to the same degree. Ucp1 expression in Cpt2A-/- BAT also 
increased with decreasing temperature but was not induced at any temperature. Basal 
Pgc1α expression was minimally altered by temperature acclimatization or genotype. 
However, it was induced by adrenergic stimulation in WT BAT to a greater degree upon 
increasing temperature, while Cpt2A-/- BAT remained non-induced under all conditions 
(Figure 3-1G). These data show that the primary transcriptional defect in Cpt2A-/- BAT is 
a failure in agonist-induced rather than basal thermogenic gene expression.  
Role of adipose fatty acid oxidation on thermogenic plasticity.  
Adipose fatty acid oxidation is required for acute cold-induced thermogenesis (36, 
93). Preacclimatization to different ambient temperatures has dramatic effects on the 
response to cold challenge. To understand the role of adipose fatty acid oxidation on the 
physiology of thermogenic plasticity, Cpt2A-/- mice were acclimatized at thermoneutrality 
(30°C) for two weeks and then placed in individual metabolic cages also housed at 30°C. 
After several days to further acclimatize the mice to the metabolic cages, control and 
Cpt2A-/- mice were injected with CL-316243 (10mg/kg) and their energy expenditure was 
monitored. As expected, Cpt2A-/- mice failed to increase their energy expenditure in 
response to β3-adrenergic stimulation and also did not drop their RER, showing that they 
exhibited less fatty acid oxidation in response to the adrenergic challenge (Figure 3-
3A,B). We then measured the energy expenditure of control and Cpt2A-/- mice at 30°C, 
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Figure 3-3. Contribution of adipose fatty acid oxidation to energy expenditure at different 
temperatures 
(A) O2 consumption of control and Cpt2A-/- mice injected with vehicle or CL-316243 (10 mg/kg) at 
thermoneutrality (n=7). 
(B) RER of control and Cpt2A-/- mice injected with either vehicle or CL-316243 (10 mg/kg) at 
thermoneutrality (n=7). 
(C) O2 consumption of control and Cpt2A-/- mice at 30°C, 22°C, and 15°C (n=7). 
(D) RER of control and Cpt2A-/- mice at 30°C, 22°C, and 15°C under dark and light cycles (n=7). 
(E) Food intake of control and Cpt2A-/- mice at 30°C, 22°C, and 15°C (n=7). 
(F) Hourly blood C18:1-carntine and L-carnitine concentrations of thermoneutral acclimatized control 
and Cpt2A-/- mice injected with CL-316243 (10 mg/kg) over 3 hr (n=5). 
(G) mRNA expression in BAT and iWAT of genes in creatine metabolism (n=5). 
Data are expressed as mean ± SEM. *p < 0.05; **p < 0.01; ***p < 0.001. 
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and directly before the dark cycle, the temperature was reduced (~1°C/4min) to 22°C 
(standard housing temperature) for 24hrs and then to 15°C for an additional 24hrs. 
Surprisingly, the energy expenditure during this paradigm of temperature shifting was 
unchanged between control and Cpt2A-/- mice (Figure 3-3C). However, consistent with 
the lack of adipose fatty acid oxidation in Cpt2A-/- mice, there was a strong shift towards 
carbohydrate oxidation as revealed by the RER (Figure 3-3D). Additionally, all mice 
showed an increase in food intake, and there was a modest increase in food consumption 
of Cpt2A-/- mice during this experimental paradigm (Figure 3-3E). These data show that 
although the Cpt2A-/- mice could not increase energy expenditure via fatty acid oxidation 
in adipose tissue, a systemic compensation enables homeostatic regulation of energy 
expenditure at different temperatures. 
Next, we wanted to better understand how mice that could not oxidize fatty acids 
in adipose tissue could maintain systemic energy homeostasis. First, we measured blood 
acylcarnitines of thermoneutral acclimatized control and Cpt2A-/- mice injected with CL-
316243 (10 mg/kg) over 3 hr. Cpt2A-/- mice were slightly carnitine deficient but exhibited 
a rise in blood long-chain acylcarnitines and a suppression of short-chain acylcarnitines 
similar to controls (Figure 3-3F; Table 3-1). These data support a systemic redistribution 
of fatty acids (93, 101). To understand possible compensatory adaptations in Cpt2A-/- 
adipose tissue, we mined our microarray data for genes in creatine metabolism (102). 
Consistent with Ucp1KO mice, Cpt2A-/- BAT exhibited an increase in Ckmt2; however, 
Cpt2A-/- BAT exhibited a loss of β3-adrenergic- induced Phospho1 expression, consistent 
with other thermogenic genes (Figure 3-3G). In addition, Cpt2A-/- iWAT exhibited 
increased β3-adrenergic induction of Ckmt1, Ckmt2, Slc6a8, and Phospho1 (Figure 3-
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3G). These data support the notion that when BAT thermogenesis is lost, temperature 
acclimatization results in systemic compensation to maintain energy homeostasis during 
gradual changes in temperature. 
Thermoneutrality induces a mitochondrial DNA stress that is potentiated by the loss of 
fatty acid oxidation.  
To determine the role of adipose fatty acid oxidation during long term housing at 
thermoneutrality, we placed control and Cpt2A-/- male mice on a high fat diet for 12 
weeks housed in a temperature- and light-controlled animal cabinet at 30°C. Upon 
necropsy, control mice had normal interscapular BAT. However, we could not identify 
morphologically distinct BAT in Cpt2A-/- mice (Figure 3-4A). Upon histological 
examination of interscapular adipose tissue, almost all of the classical BAT morphology 
was absent (Figure 3-4B). The loss of adipose tissue triglyceride lipase results in a 
suppression of Pparα, and therefore a switch of identity from BAT to a more WAT-like 
identity (65; 100). We do not observe defects in Pparα or Pparα target genes at baseline 
(Figure 3-1D). Additionally Cpt2A-/- BAT does not exhibit alterations in BAT specific 
identity (Figure 3-1C). However, increasing ambient temperature potentiated the loss of 
mitochondrial DNA in Cpt2A-/- BAT (Figure 3-4C). These data suggest that adipose fatty 
acid oxidation is required to maintain BAT at thermoneutrality. 
The loss of mitochondrial DNA via genetic deletion of the mitochondrial 
transcriptional regulator Tfam was shown to induce Interferon Stimulated Genes (ISG) 
and initiate an innate antiviral response (103). Microarray analysis of thermoneutral 
acclimatized Cpt2A-/- BAT identified a similar gene expression profile. A broad range of 
ISGs such as Oasl2, Ifih1, Sp110 and p200 family proteins Ifi203 and Ifi204 were  
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Figure 3-4. Loss of Fatty Acid Oxidation Potentiates Mitochondrial DNA Stress 
(A) Gross interscapular BAT morphology of control and Cpt2A-/- mice after 12 weeks of high-fat (HF) 
diet at thermoneutrality. 
(B)  H&E-stained BAT from control and Cpt2A-/- mice after 12 weeks of HF diet at thermoneutrality. 
Arrows indicate BAT morphology. Scale bar, 100 mM. 
(C) mtDNA fold suppression of control and Cpt2A-/- BAT at 15°C and 30°C (n=5). 
(D) mRNA expression in BAT of ISGs in BAT of control and Cpt2A-/- mice injected with vehicle or 
CL-316243 at thermoneutrality (n=5). 
(E) mRNA expression in BAT of ISGs in control and Cpt2A-/- mice after 2 weeks at 15°C, 21°C, and 
30°C (n=5). 
Data are expressed as mean ± SEM. *p < 0.05; **p < 0.01; ***p < 0.001. 
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induced in Cpt2A-/- BAT. We went on to verify a subset of these genes (Pyhin1, Ifit1, 
Ifit3, Usp18, Isg15, Irf7, Viperin and Ifi44) by qRT-PCR (Figure 3-4D). Interestingly, 
these genes were induced regardless of adrenergic stimulation. In fact, adrenergic 
stimulation suppressed these genes in both control and Cpt2A-/- BAT (Figure 3-4D). To 
determine the role of ambient temperature on the regulation of these ISGs, we profiled a 
subset of genes (Pyhin1, Irf7, Ifi44, Ifit3, Usp18 and Viperin) in control and Cpt2A-/- BAT 
from mice acclimatized to 15°C, 21°C, and 30°C. All of the ISGs increased in BAT as 
ambient temperature increased, and the loss of fatty acid oxidation greatly potentiated 
this response (Figure 3-4E). These data show that temperature imparts a mitochondrial 
DNA stress in BAT and this is greatly potentiated by a loss in mitochondrial fatty acid β-
oxidation. 
The absence of adipose fatty acid oxidation does not affect obesity at thermoneutrality. 
Thermoneutrality has been shown to dramatically and acutely increase weight 
gain of Ucp1KO mice, particularly when they are fed a high fat diet (81). We predicted 
that thermoneutrality would impart an obesogenic phenotype on Cpt2A-/- mice since 
Ucp1KO and Cpt2A-/- mice have a similar degree of cold intolerance. Cpt2A-/- BAT is 
bioenergetically and transcriptionally incompetent for thermogenesis, and long-term 
housing at 30°C facilitates an almost complete loss of BAT. Therefore, we measured the 
body weight weekly of control and Cpt2A-/- mice for 12 weeks fed a high fat diet and 
housed at 30°C. Surprisingly, thermoneutral housing did not affect weight gain in Cpt2A-/- 
mice (Figure 3-5A). Adiposity was also not affected and even trended lower (Figure 3-
5B,C), similar to high fat feeding at room temperature (93). Additionally, there was no 
change in glucose tolerance (Figure 3-5D), little change in serum chemistry 
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Figure 3-5. The Loss of Adipose Fatty Acid Oxidation Does Not Potentiate Diet-Induced Obesity at 
Thermoneutrality 
(A) Body weights of control and Cpt2A-/- male mice fed a high-fat diet from 6 weeks of age at 
thermoneutrality (n=11–13). Arrow indicates the beginning of the high-fat diet. 
(B) Fat and lean mass of control and Cpt2A-/- mice at 18 weeks of age after 12 weeks on a high-fat diet 
at thermoneutrality (n=11–13). 
(C) Wet weights of iWAT, gWAT (unilateral depots), and liver (left lobe) of control and Cpt2A-/- mice 
(n=11–13). 
(D) Intraperitoneal glucose tolerance test (ipGTT), including the area under the curve (AUC), for 
control and Cpt2A-/- mice at 10 weeks on a high-fat diet at thermoneutrality (n=11–13). 
(E) Serum metabolite levels of control and Cpt2A-/- mice fed a high-fat diet at thermoneutrality (n=9). 




Figure 3-6. Transcriptional response of control and Cpt2A-/- iWAT to a high fat diet at 
thermoneutrality, related to Figure 3-5. 
(A) mRNA expression in iWAT of thermogenic genes (n=5). 
(B) mRNA expression in iWAT of Pparα and Pparα target genes (n=5). 
(C) mRNA expression in iWAT of interferon responsive genes (n=5). 
Data are expressed as mean ± SEM. *p<0.05. 
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(Figure 3-5E), and no significant beiging of iWAT (Figure 3-6) upon deletion of 
mitochondrial fatty acid β-oxidation in adipose tissue. These data suggest that defects in 
adipose tissue bioenergetics alone cannot account for the etiology of obesity or diabetes. 
Discussion 
BAT gene expression and thermogenic potential are highly correlated with the 
regulation of body weight and susceptibility to high fat diet induced obesity across many 
mouse models (24). The loss of Ucp1 (34, 79) or adipose fatty acid oxidation (36, 93) 
generates severe cold intolerance but does not result in susceptibility to diet induced 
obesity under standard laboratory housing conditions. Therefore, it seems unlikely that 
mice with an obesogenic phenotype at room temperature can be explained via a defect in 
BAT bioenergetics alone. Thermoneutrality revealed an obesogenic phenotype of 
Ucp1KO mice (81), however, we were not able to recapitulate this effect in Cpt2A-/- mice 
although they had molecular, cellular and biochemical defects that prevented canonical 
BAT function. Our results suggest that, although BAT dysfunction is tightly correlated 
with obesity, BAT function itself is likely correlating with the main driver of whole body 
energy expenditure that has yet to be defined mechanistically. In support of this notion, 
Fgf21 has a strong effect on BAT but can increase energy expenditure and induce weight 
loss equally well in wild-type or Ucp1KO mice even at thermoneutrality (6, 104-106). 
Additionally, the transplantation of large quantities of BAT in mice produced only mild 
benefits to body weight gain that were dependent on Il-6, suggesting an endocrine rather 
than bioenergetic role of BAT (3). 
Triglyceride lipolysis and fatty acid oxidation are largely interdependent. 
Consequently, the loss of the rate-setting step in triglyceride hydrolysis, Adipocyte 
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Triglyceride Lipase (Atgl), results in cold intolerance (65). Interestingly, the knockout of 
Atgl with ap2/Fabp4-Cre generates mice that are obese with increased adiposity (65). 
However, the knockout of Atgl with the more specific adiponectin-Cre generates mice 
that are not more prone to obesity even after high fat feeding (100). This suggests that the 
increase in body weight and adiposity induced by a loss in adipocyte triglyceride 
hydrolysis requires simultaneous deletion in cells other than adipocytes (such as 
macrophages). Additionally, the loss of Atgl results in the loss of Pparα directed 
transcription and the loss of BAT identity presumably from the loss of an endogenous 
Pparα ligand produced upon hydrolysis (65, 98-100). Cpt2 deficient BAT maintains a 
BAT-like transcriptional program, and is not deficient in Pparα-mediated transcription. In 
fact, there is more Pparα target gene expression in Cpt2A-/- BAT likely due in part to the 
increase in basal adrenergic activity and PKA signaling (93). The main defect in Cpt2A-/- 
BAT is due to the loss in adrenergic-induced gene expression with limited changes to 
basal gene expression. Although lipolysis and β-oxidation are intimately linked within a 
continuous pathway, these data show that fatty acid catabolism affects transcription at 
multiple independent steps suggesting a complex integration of metabolites and 
transcriptional programming. 
One of the most surprising results from the current study was the increase in ISGs 
in Cpt2A-/- BAT. The loss of Cpt2 and the loss of Tfam have a high degree of concordance 
between the ISGs induced (103). However, the suppression in mitochondrial DNA was 
specific to BAT in Cpt2A-/- mice as mtDNA was unchanged in gWAT, iWAT or MEFs 
deleted in Cpt2 (93). This suggests that cells that undergo high fatty acid oxidation may 
be more susceptible to mtDNA stress, while Tfam loss affects mtDNA stress more 
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globally. It will be interesting to see if other tissue specific KOs of Cpt2 enhance innate 
immune priming, particularly macrophages. The mtDNA stress and ISG expression was 
increased in wild-type mice with increasing temperature, and this was greatly potentiated 
by the loss of fatty acid oxidation. Thermoneutrality exhibits a broad array of beneficial 
physiologic adaptations not overtly associated with energy homeostasis, including 
significant improvements in tumor therapy (107, 108). It is tempting to speculate that 
thermoneutrality initiates a priming of the innate immune system via mitochondrial 
metabolism that improves tumor clearance and antiviral activity. 
Small mammals with large surface to volume ratios can expend a large amount of 
energy defending their body temperatures against the environment and have a large 
capacity for thermogenesis. Altering the ambient temperature results in an amazing array 
of molecular, cellular and physiological adaptations to maintain body temperature and 
energy homeostasis. Adipocyte fatty acid oxidation plays a major role in both mediating 
and regulating these processes. Mice with an adipose specific loss of fatty acid oxidation 
are unable to maintain their body temperature during an acute cold challenge (93). 
However, in response to moderate environmental challenges, they are able to maintain 
energy homeostasis via alternative mechanisms. The control of energy expenditure 
represents a critical evolutionarily conserved survival mechanism that is likely regulated 
by multiple overlapping and compensatory systems, which may present a continuing 
challenge for treatments aimed at reversing human obesity. 
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Table 3-1. Blood acylcarnitine profile of thermoneutral acclimatized Cpt2lox/lox and Cpt2A-/- mice 
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Starvation initiates a series of metabolic adaptations to enable continuous 
production and delivery of nutrients to critical organs, tissues and cells (53).  This 
response is coordinated in large part by the liver that responds by liberating glucose to the 
circulation initially from glycogen stores followed by de novo glucose production (i.e. 
gluconeogenesis).  Additionally, ketones are produced and provide an alternative energy 
source to glucose for highly oxidative tissues such as the brain (55).  Fatty acid oxidation 
is critical for these processes as it provides the carbon substrate for ketogenesis (acetyl-
CoA) and mitochondrial bioenergetics (ATP, NADH) to facilitate gluconeogenesis.  
Therefore, humans with disparate inborn errors in mitochondrial fatty acid oxidation 
exhibit life-threatening hypoketotic-hypoglycemia following a fast (54). Systemically, the 
liver produces most of the circulating ketones due to its high capacity for β-oxidation and 
lack of the CoA transferase (Oxct1) in hepatocytes that is required to utilize ketones (56).  
Also, the liver is thought to dominate fasting gluconeogenesis with minor contributions 
from the kidney and gut.  Interestingly, mice with a hepatocyte-specific loss of glucose-6-
phosphatase, the obligate terminal enzyme in cellular glucose liberation, do not exhibit 
reduced blood glucose following fasting or starvation, although ketone production is 
accelerated (57).  Therefore, extra-hepatic gluconeogenic tissues can fully compensate for 
a loss of hepatic production.   
Mitochondrial long chain fatty acid β-oxidation is governed by the regulated 
translocation of activated fatty acids (acyl-CoAs) from the cytoplasm to the 
mitochondrial matrix mediated by successive carnitine acyltransferases (58).  Carnitine 
Palmitoyltransferase 1 (Cpt1) isoenzymes mediate acyl transfer from long chain acyl-
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CoAs to carnitine on the outer mitochondrial membrane, generating acylcarnitines that 
can traverse through the Carnitine-acylcarnitine translocase within the inner 
mitochondrial membrane.  Within the mitochondrial matrix, Cpt2 transfers the acyl group 
from the acylcarnitine back onto CoA, enabling β-oxidation.  Human inborn errors in 
Cpt2 result in increasing severity of metabolic disease (OMIM #s, 255110 adult onset, 
600649 infantile, and 600650 infantile lethal) (28, 59).  The complete loss of Cpt1a or 
Cpt1b is embryonic lethal in mice, and the loss of Acadl or Acadm results in increased 
neonatal death (29, 30, 60).  The loss of other mitochondrial components of β-oxidation 
result in multisystemic defects as well as cell-specific compensatory mechanisms (39, 61-
63).  
To understand the contribution of hepatic fatty acid oxidation during fasting and 
starvation, we generated mice with a liver-specific knockout of Carnitine 
Palmitoyltransferase 2 (Cpt2L-/-), an obligate enzyme in mitochondrial long chain fatty 
acid β-oxidation encoded by a single gene.  To our great surprise, Cpt2L-/- mice not only 
survived the perinatal period but also did not exhibit alterations in blood glucose 
following a 24hr fast although ketones were absent.  Fasting resulted in serum 
dyslipidemia, hepatic steatosis and alterations in hepatic and systemic oxidative gene 
expression.  Although Cpt2L-/- mice were able to adapt to survive a 24hr fast, feeding 
them a ketogenic diet resulted in hepatomegaly and death after only 6 days with a 
complete absence of adipose triglyceride stores.  These data show that hepatic fatty acid 
oxidation is not required for survival during acute food deprivation, but is essential for 





To generate a liver-specific loss-of-function of Cpt2, we bred Cpt2lox/lox mice (64) to 
albumin-Cre transgenic mice (65). Mice were housed in ventilated racks with a 14 hr 
light/10 hr dark cycle and fed a standard chow diet (Harlan Laboratories). All mice were 
euthanized at the same time of day (3p.m.). Fed mice were food deprived from 1 p.m.-3 
p.m. to ensure consistent feeding patterns.  For fasting studies, mice were deprived of 
food for 24 hours from 3p.m.-3 p.m. For the ketogenic diet studies, mice were placed on 
a ketogenic diet at 9 weeks of age (66). Serum was collected for all mice to measure free 
glycerol and TAG (Sigma), β-hydroxybutyrate (StanBio), total cholesterol, NEFA 
(Wako), and ALT (Sigma). Fgf21, Gdf15, Igfbp1, Corticosterone, Adiponectin (R&D 
systems) and insulin (Millipore) and Adiponectin were measured by ELISA. Body fat 
and lean mass of 9-week old mice was measured via magnetic resonance imaging 
analysis (QNMR EchoMRI100; Echo Medical Systems, LLC).  Indirect calorimetry and 
metabolic cage studies were normalized to total lean mass as described (67). All 
procedures were performed in accordance with the NIH’s Guide for the Care and Use of 
Laboratory Animals and under the approval of the Johns Hopkins Medical School 
Animal Care and Use Committee. 
Metabolic measurements 
Blood levels of acylcarnitines were quantified from dried blood spots (DBS) with 
modifications (68, 69). Punched 1/8″ DBS samples were submerged in 100 μl of 
methanol solution containing internal standards for acyl carnitines (NSK B, Cambridge 
Isotopes).  Samples were incubated at 4°C for 20min, dried under nitrogen and then 60 μl 
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3N HCl in n-butanol was added. The samples were incubated for 15 min at 65 °C then 
dried under LN2, and butylated acyl carnitines were reconstituted in 100μl of mobile 
phase acetonitrile/water/formic acid (H2O:CH3CN:HCOOH; 80:19.9:0.1 v/v%). Samples 
were vortexed, transferred to a centrifuge filter, spun and transferred to an injection vial. 
Tissue acyl carnitines were isolated from freeze-clamped tissue and homogenized in a 
methanol solution containing internal standards as above, sonicated for 10min at room 
temperature and centrifuged for 4min at 13,000rpm at 4°C. Following centrifugation, the 
liquid phase was collected and evaporated to dryness under LN2 and processed as above. 
Acyl carnitines were analyzed on an API 3200 (AB SCIEX, Foster City, CA) operated in 
positive ion mode employing precursor ion scan for m/z 85, which is generated as a 
characteristic product ion of butyl ester of acyl carnitine species. Quantitation of acyl 
carnitines was achieved by Chemoview (AB SCIEX) application. All blood samples are 
reported as nmol/ml; tissue samples as pmol/mg.  Liver fatty acid oxidation, TAG 
measurement and liver peroxidation was done as previously described (66, 67).   
Real Time qPCR  
RNA was isolated from all tissues using the RNeasy Mini Kit (QIAGEN). Using the 
High Capacity cDNA Reverse Transcription Kit (Applied Biosystems), we reverse 
transcribed 1-2 ug of total RNA. The cDNA was diluted to 2ng/uL and amplified by 
primers in a 20 uL reaction using SsoAdvanced SYBR Green Supermix (Bio-Rad). The 
analysis was done using a CFX Connect Real-Time System (Bio-Rad). We calculated 
mRNA using a 2∧deltaCT relative to the average of the housekeeping genes cyclophilin A, 




Liver and kidney homogenates were prepared using 1× RIPA buffer with protease 
inhibitors. The protein concentration was measured using the Pierce BCA Protein Assay 
kit (Thermo Scientific). We used 30 ug of protein on an SDS-PAGE and then transferred 
it to either a nitrocellulose (Protran BA 83, Whatman) or a polyvinylidene difluoride 
(PVDF) membrane. We then blocked with 3% BSA-TBST (tris buffer saline with tween 
20). The membranes were then probed with antibodies Cpt2 (Pierce), Pgc1α (Abcam), 
Acsl1 (Cell Signaling), Acot1 (Cell Signaling), Acot2 (Cell Signaling), Cpt1α (Abcam), 
Acadm (GeneTex), Acsf3 (Pierce), Total Acc (Cell Signaling), Acly (Cell Signaling), 
Hadha (Genetex), Aco2 (Cell Signaling), Fasn (BD Biosciences), and Hsc70 (Santa Cruz 
Biotechnology). Hsc70 used the appropriate Cy3 fluorescent secondary antibodies, and 
the other primary antibodies used the corresponding secondary antibodies conjugated to 
horseradish peroxidase.  
Statistical Analysis 
Data were analyzed with the assistance of Prism.  Significance was determined using an 
unpaired two-tailed Student’s t-test for single variable experiments and two-way 
ANOVA with Bonferroni post hoc correction for multiple variable experiments. 
RESULTS 
Generation of mice with a liver-specific deficiency in fatty acid β-oxidation.  
Previously, we generated a mouse model with a conditional loss-of-function allele 
for Cpt2, an obligate step in mitochondrial long chain fatty acid β-oxidation (64, 70). To 




Figure 4-1. Characterization of mice with a liver specific KO of CPT2.   
(A) Western blot for CPT2 in liver of Cpt2lox/lox and Cpt2L-/- mice. 
(B) mRNA for Cpt2 across different tissues (n=6). 
(C) Oxidation of 1-14C-oleic acid and 1-14C-Lignoceric acid to 14CO2 in liver slices of Cpt2lox/lox and 
Cpt2L-/- mice (n=5). 
(D) Body weights of Cpt2lox/lox and Cpt2L-/- male and female mice fed a normal chow diet (males, 
n=14-23; females, n=8-12). 
Data are expressed as mean ± SEM. *p<0.05; **p<0.01; ***p<0.001. 
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liver-specific albumin-Cre transgenic mice (65). The resulting liver-specific Cpt2 
knockout (KO) mice (Cpt2L-/-) showed a loss of CPT2 protein in the liver (Figure 4-1A) 
and decreased mRNA levels of Cpt2 specifically in the liver (Figure 4-1B). As expected, 
oleate oxidation was significantly suppressed in the liver of Cpt2L-/- mice to a similar 
degree as incubation with 100μM of the CPT inhibitor, etomoxir (71). There was no 
change in the oxidation of the very long chain fatty acid, lignoceric acid, which is 
preferentially oxidized in peroxisomes (Figure 4-1C). Although males had a small 
suppression of body weight after weaning, females did not show suppressed body weight 
and all mice exhibited normal body weight by 6 weeks of age (Figure 4-1D).  These data 
show that the loss of hepatic mitochondrial long chain fatty acid β-oxidation is not 
required for survival to adulthood. This is surprising given the requirement for fatty acid 
β-oxidation during the perinatal period (39, 72, 73).      
Fasting results in hypoketotic dyslipidemia in Cpt2L-/- mice.  
To determine the requirements for hepatic fatty acid oxidation upon food 
deprivation, we fasted Cpt2lox/lox and Cpt2L-/- mice for 24 hours at 9 weeks of age. As 
expected, there was a significant decrease in serum β-hydroxybutyrate (βHB) in Cpt2L-/- 
mice even in the fed state.  Control Cpt2lox/lox mice dramatically increased serum βHB 
upon a 24hr fast as expected while Cpt2L-/- mice did not exhibit appreciable serum βHB 
consistent with the a loss of hepatic fatty acid oxidation (Figure 4-2A). Additionally, 
fasting induced serum dyslipidemia with increased NEFA and cholesterol in Cpt2L-/- mice 
(Figure 4-2A).  Cpt2L-/- mice did not become hypoglycemic following the 24hr fast nor 
was insulin different between genotypes (Figure 4-2A).  Because the liver plays an 




Figure 4-2.  Liver and systemic deficits in fed and 24hr fasted Cpt2L-/- mice. 
(A) Serum metabolites in Cpt2lox/lox and Cpt2L-/- mice (n=6). 
(B) Energy expenditure and respiratory exchange ratio of Cpt2lox/lox and Cpt2L-/- mice under fed, fast 
and refed conditions (males, n=5-7). 
(C) Total fat and lean mass of Cpt2lox/lox and Cpt2L-/- male mice (n=5-7). 
(D) Total fat and lean mass of Cpt2lox/lox and Cpt2L-/- male mice (n=5-7). 
(E) Wet weights of fed or 24 hour fasted iWAT, gWAT, and liver for Cpt2lox/lox and Cpt2L-/- mice 
(n=6-10).  
(F) Gross and histological morphology of livers from 24 hr fasted Cpt2lox/lox and Cpt2L-/- mice.  
(G) Triglyceride levels from liver homogenates of fed and 24 hr fasted Cpt2lox/lox and Cpt2L-/- mice 
(n=5). 
(H) Liver damage measured by serum ALT activity of fed and 24hr fasted Cpt2lox/lox and Cpt2L-/- mice 
(n=5). 
(I) Liver damage measured by serum ALT activity of fed and 24h fasted Cpt2lox/lox and Cpt2L-/- mice 
(n=5). 
(J) TBARS assay measuring lipid peroxidation from liver of fed and 24 hr fasted Cpt2 lox/lox and Cpt2L-
/- mice (n=5). 




Figure 4-3. Corticosterone, ER stress, body composition and whole body bioenergetics of Cpt2lox/lox 
and Cpt2L-/- mice. 
(A) Respiratory exchange ratio and energy expenditure in fed fast and refed Cpt2lox/lox and Cpt2L-/- 
female mice (n=6). 
(B) Total fat and lean mass of Cpt2lox/lox and Cpt2L-/- female mice (n=6). 
(C) Ambulatory activity and food intake during fed, fast and refed Cpt2lox/lox and Cpt2L-/- female mice 
(n=6). 
(D) Ambulatory activity and food intake during fed, fast and refed Cpt2lox/lox and Cpt2L-/- male mice 
(n=5-7). 
(E) Serum concentration of Corticosterone in fed, 24h fasted and ketogenic diet-fed Cpt2lox/lox and 
Cpt2L-/- male mice (n=5). 
(F) Gene expression of Atf4, Chop, Xbp(s) and Xbp(t) in the liver of fed, 24h fasted and ketogenic 
diet-fed Cpt2lox/lox and Cpt2L-/- male mice (n=6). 




bioenergetics in Cpt2L-/- mice. Interestingly, there was no change in energy expenditure 
between Cpt2lox/lox and Cpt2L-/- mice in fed, fasted, or refed states (Figure 4-2B). 
Although Cpt2L-/- mice exhibit clear metabolic deficiencies, in the context of whole 
animal energy homeostasis, Cpt2lox/lox and Cpt2L-/- mice were able to maintain equivalent 
energy expenditure and respiratory exchange ratio even during fasting (Figure 4-2B). 
Food intake, body composition, and ambulatory activity were not different between male 
and female Cpt2lox/lox and Cpt2L-/- mice (Figures 4-2C and 4-3A-3D). Examination of 
tissue weights in Cpt2lox/lox and Cpt2L-/- mice showed that fasting resulted in a greater 
suppression in gonadal white adipose tissue (gWAT) in Cpt2L-/- mice while there was a 
concomitant increase in liver weight (Figure 4-2D). Consistent with the wet weight data, 
Cpt2L-/- livers were enlarged and lipid laden following a 24-hour fast (Figure 4-2E). 
Liver triglyceride levels were unchanged in the fed state but were significantly increased 
in Cpt2L-/- mice compared to control Cpt2lox/lox mice upon fasting (Figure 4-2F). There 
were no signs of liver damage by serum ALT activity (Figure 4-2G), altered 
corticosterone levels (Figure 4-3E), or significant markers of ER stress (Figure 4-3F) 
following a 24hr fast. There were no signs of liver damage by serum ALT activity 
(Figure 4-2G), altered corticosterone levels (Figure 4-3E), or significant markers of ER 
stress (Figure 4-3F) following a 24 hour fast.  However, However, Cpt2L-/- livers did 
show did show significant lipid peroxidation following fasting (Figure 4-2H).  These 
data show that mice with a loss of hepatic fatty acid β-oxidation can adapt to maintain 
systemic energy homeostasis during a fast but not without adverse consequences to the 
liver and adipose tissue stores. 
 79 
Fasting increases oxidative and suppresses lipogenic programing in livers of Cpt2L-/- 
mice.   
Given the robust physiological and cellular adaptations in Cpt2L-/- mice, we 
determined hepatic gene expression of select fatty acid metabolic genes in fed and fasted 
Cpt2lox/lox and Cpt2L-/- mice.  First we determined the expression of fatty acid oxidation 
genes. In the fed state, there were increases in acsl1, acot1 and acot2 mRNA in the livers 
of Cpt2L-/- mice (Figure 4-4A). Acot1 and Acot2 were also increased at the protein level 
in the livers of fed Cpt2L-/- mice (Figure 4-4B).  Following a 24-hour fast, the increases 
in acot1 and acot2 in the livers of fed Cpt2L-/- mice were greatly exacerbated as well as 
increases in the fatty acid oxidative genes, Acox1, AcadL and Hadha (Figure 4-4A). 
These changes were largely mirrored at the protein level by western blotting (Figure 4-
4B). Many of the fatty acid biosynthetic genes were suppressed following a 24hr fast in 
livers of Cpt2L-/- mice compared to Cpt2lox/lox mice (Figures 4-4B and 4-5A). 
Gluconeogenic gene expression was not altered in Cpt2L-/- mice with the exception of 
Pck2 whose contribution to gluconeogenesis is not well defined (Figure 4-6A). 
Gluconeogenic gene expression was not altered in Cpt2L-/- mice with the exception of 
pck2 whose contribution to gluconeogenesis is not well defined (Figure 4-6A). These 
data show a robust up-regulation of fatty acid catabolic genes and suppression of fatty 
acid anabolic genes in the livers of Cpt2L-/- mice that were exacerbated by fasting.  This 
suggests that the fatty acid oxidation deficient livers were attempting to compensate for 
the lack of fatty acid oxidation in the face of a large lipid burden. 
Fasting induces Pparα target genes and procatabolic hepatokines Fgf21, Gdf15, and 




Figure 4-4. Loss of hepatic fatty acid oxidation induces expression of fatty acid oxidative genes. 
(A) Gene expression of fatty acid oxidation genes in liver of fed and 24 hr fasted Cpt2lox/lox and Cpt2L-
/- mice (n=6). 
(B) Western blots of proteins in fatty acid metabolism. Composite of 8 blots. All blots were 
normalized to Hsc70 (Figure 4-S2). 
(C) Liver mRNA (n=6) and serum concentrations (n=8) of Fgf21, Gdf15 and Igfbp1 in fed and 24 hr 
fasted Cpt2lox/lox and Cpt2L-/- mice. 
(D) Serum concentration (n=8) of Fgf21, Gdf15 and Igfbp1 in fed and 24-hr fasted Cpt2lox/lox and 
Cpt2L-/- mice. 




Figure 4-5. The loss of liver fatty acid oxidation alters fatty acid metabolism in the liver. 
(A) Gene expression of de novo fatty acid biosynthesis genes of fed and 24h fasted Cpt2lox/lox and 
Cpt2L-/- mice (n=6). 
(B) Western blots of proteins involved in fatty acid metabolism with Hsc70 as loading control (n=3).  






Figure 4-6. Gluconeogenic gene expression, cardiac and kidney fatty acid metabolism. 
(A) Gene expression of gluconeogenic genes Pck1, Pck2, G6pase and Pcx in liver of fed and 24h 
fasted Cpt2lox/lox and Cpt2L-/- mice (n=6). 
(B) Gene expression of gluconeogenic genes Pck1, Pck2, G6pase and Pcx in kidney of fed and 24h 
fasted Cpt2lox/lox and Cpt2L-/- mice (n=6). 
(C) Gene expression of fatty acid oxidation genes in the heart of fed and 24h fasted Cpt2lox/lox and 
Cpt2L-/- mice (n=6). 
(D) Western blots of fatty acid oxidation genes in the kidney with corresponding Hsc70 for each blot 
as a loading control. 
Data are expressed as mean ± SEM. *p<0.05; **p<0.01; ***p<0.001. 
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Due to the robust transcriptional response in Cpt2L-/- mice, we decided to probe 
further into the transcriptional alterations in the livers of Cpt2L-/- mice.  Therefore, we 
fasted Cpt2lox/lox and Cpt2L-/- mice for 24hrs for genome wide gene expression profiling 
on liver mRNA via DNA microarrays (Table 4-1).  Microarray analysis revealed a 
dramatic transcriptional dysregulation in the livers of Cpt2L-/- mice upon fasting.  In order 
to validate the microarray results in a larger cohort of mice, we analyzed a subset of 
genes identified in the microarray analysis by qRT-PCR in both fed and fasted Cpt2lox/lox 
and Cpt2L-/- mice (Table 4-1). Consistent with the robust transcriptional and protein 
induction of Acot1 and Acot2, other type I ACOTs, canonical Pparα target genes, were 
also identified in the microarray.  Other canonical Pparα target genes were also 
dramatically up-regulated such as pdk4 (~100 fold), ehhadh (~50 fold), cd36, (~10 fold), 
and fabp3 (~160 fold) (Table 4-1).  These data suggest that exogenous fatty acid derived 
Pparα ligands build up in the face of increased lipid delivery to the liver and are greatly 
potentiated in the absence of mitochondrial fatty acid oxidation.     
 We were surprised that although Cpt2L-/- mice had clear metabolic deficiencies, 
they were able to maintain systemic energy homeostasis even following a 24hr fast.  
Therefore, we were interested in determining how the Cpt2L-/- liver might be 
communicating these deficits with other tissues.  Of interest was one of the most highly 
up-regulated genes in the livers of Cpt2L-/- mice (~50 fold), the secreted hepatokine fgf21 
(Table 4-1, Figure 4-4C). Fgf21 is also a canonical Pparα target gene (74, 75). 
Consistent with the transcriptional increase in fgf21, serum Fgf21 was increased (~11.5 
fold) in fasted Cpt2L-/- mice compared with Cpt2lox/lox littermate controls (Figure 4-4D).  
Additionally, gdf15 and igfbp1 mRNA were increased in fasted Cpt2L-/- liver and these 
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were also increased to a similar degree in Cpt2L-/- serum (Figures 4-4C, D). These 
secreted proteins have all been shown to increase systemic catabolism (74-78).  These 
data suggest that the loss of hepatic fatty acid oxidation is mitigated in part by increasing 
systemic procatabolic hepatokines.   
Fasting induces systemic catabolic gene expression in Cpt2L-/- mice. 
 Some metabolic processes that occur largely in the liver, such as gluconeogenesis, 
can be supplanted in part by the kidney.  Therefore, we postulated that the kidney could 
be a major site of systemic compensation of energy homeostasis.  First, we assessed the 
regulation of oxidative gene expression in the kidneys of fed and 24hr fasted Cpt2lox/lox 
and Cpt2L-/- mice.  Fasting initiated a robust increase in the expression of genes involved 
in fatty acid oxidation in the kidneys of Cpt2L-/- mice similar to the elevation in liver 
(Figure 4-7A).  A subset of these genes was also validated at the protein level (Figure 4-
7B). Similar to the liver, gluconeogenic gene expression was not altered in Cpt2L-/- mice 
with the exception of Pdk2 (Figure 4-6B). Similar to the liver, gluconeogenic gene 
expression was not altered in Cpt2L-/- mice with the exception of pck2 (Figure 4-6B). 
Upon dissection, the kidneys of 24hr fasted Cpt2L-/- mice were visibly lipid laden (Figure 
4-7C). Although the wet weight of the kidneys of Cpt2lox/lox and Cpt2L-/- mice were 
similar, the kidneys of Cpt2L-/- mice exhibited a ~2fold increase in total triglycerides 
consistent with increased uptake of fatty acids (Figures 4-7D,E).  These data support the 
kidney as a major site of compensation in fasted Cpt2L-/- mice. 
 Fgf21 has been shown to regulate ketogenic and oxidative genes in the liver in an 
autocrine manner.  Fgf21 has also been postulated to affect adipocyte energy balance in 
an endocrine manner (79).  Since fasting induces a robust increase in circulating Fgf21 in 
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Cpt2L-/- mice, we examined the some of the putative endocrine effects of Fgf21 treatment 
in a more physiological model.  Interscapular BAT (iBAT) of Cpt2L-/- mice did not 
exhibit transcriptional increases in thermogenic genes (Figure 4-7F), but fasting elicited 
increases in ucp1, cidea and fgf21 in inguinal WAT (iWAT) of Cpt2L-/- mice (Figure 4-
7G) consistent with fasting induced Fgf21 target gene expression in this tissue (80).  
Adipose-derived Adiponectin has also been shown to be a pharmacologic target of Fgf21 
(81, 82).  However, we did not observe an increase in adiponectin mRNA in gonadal 
WAT (gWAT) nor did we observe changes in serum Adiponectin between fed or fasting 
Cpt2lox/lox and Cpt2L-/- mice (Figure 4-7H). Due to the robust contribution of skeletal 
muscle and heart to whole body fatty acid oxidation, we examined fatty acid oxidative 
gene expression in these tissues. Although the transcriptional response was not as robust 
as the kidney in these tissues, fasting induced a significant increase in Acot1 and Acot2 in 
Cpt2L-/- gastrocnemius muscle (Figure 4-7I) an induced a significant increase in Acot1 in 
the Cpt2L-/- heart (Figure4-6C). Interestingly, along with liver and iWAT, skeletal 
muscle of Cpt2L-/- mice also exhibited a significant fasting-induced increase in Fgf21 
expression (Figure 4-7J). Together, these data suggest that loss of hepatic fatty acid 
oxidation may be mitigated in part by the induction of procatabolic hepatokines such as 
Fgf21 via both cell autonomous and non-cell autonomous mechanisms via both cell 
autonomous and non-cell autonomous mechanisms.    
A ketogenic diet depletes adipose triglyceride stores and is lethal to Cpt2L-/- mice.  
Given the putative requirements for hepatic fatty acid oxidation, we were 





Figure 4-7. Loss of hepatic fatty acid oxidation results in compensation from the kidney, muscle and 
adipose tissue. 
(A) Gene expression of fatty acid oxidation genes in the kidney of fed and 24 hr fasted Cpt2 lox/lox and 
Cpt2L-/- mice (n=6). 
(B) Western blots of proteins in fatty acid metabolism. Composite of 5 blots. All blots were 
normalized to Hsc70 (Figure 4-S3). 
(C) Gross kidney morphology in 24 hr fasted Cpt2lox/lox and Cpt2L-/- mice. 
(D) Kidney wet weight of fed and 24 hr fasted Cpt2lox/lox and Cpt2L-/- mice (n=6-10). 
(E) Kidney TAG content of fed and 24 hr fasted Cpt2lox/lox and Cpt2L-/- mice (n=5). 
(F) iBAT gene expression of fed and 24 hr fasted Cpt2lox/lox and Cpt2L-/- mice (n=6). 
(G) iWAT gene expression of fed and 24 hr fasted Cpt2lox/lox and Cpt2L-/- mice (n=6). 
(H) gWAT adiponectin mRNA (n=6) and Adiponectin serum concentration (n=8) of fed and 24 hr 
fasted Cpt2lox/lox and Cpt2L-/- mice. 
(I) Gene expression of fatty acid oxidation genes in the gastrocnemius muscle of fed and 24 hr fasted 
Cpt2lox/lox and Cpt2L-/- mice. (n=6). 
(J) Gastrocnemius muscle mRNA of Fgf21 in fed and 24 hr fasted Cpt2lox/lox and Cpt2L-/- mice (n=6). 
(K) Gene expression of fatty acid oxidation genes in the gastrocnemius muscle of fed and 24 hr fasted 
Cpt2lox/lox and Cpt2L-/- mice (n=6). 
(L) Gastrocnemius muscle mRNA of Fgf21 in fed and 24 hr fasted Cpt2lox/lox and Cpt2L-/- mice (n=6). 
Data are expressed as mean ± SEM. *p<0.05; **p<0.01; ***p<0.001. 
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would tolerate a long-term carbohydrate-limited diet, we placed 9-week old Cpt2lox/lox 
and Cpt2L-/- mice on a low carbohydrate ketogenic diet.  After 6 days on the ketogenic 
diet, several Cpt2L-/- mice died and the remaining Cpt2L-/- mice exhibited a dramatic 
weight loss (Figure 4-8A). Cpt2L-/- mice exhibited hepatomegaly (Figure 4-8B) and 
significant liver damage as measured by serum ALT activity (Figure 4-8C). These 
physiologic indicators were accompanied by severe kyphosis and lethargy, suggesting a 
neurologic involvement.   Additionally, Cpt2L-/- mice became hypoglycemic and 
hypoketotic with corresponding serum dyslipidemia (Figure 4-8D).  Incredibly, upon 
dissection, Cpt2L-/- mice completely lacked observable white adipose tissue following 6 
days on a ketogenic diet, consistent with the loss of body weight (Figure 4-8E).  These 
data suggest that from a physiological standpoint, Cpt2L-/- mice could not differentiate 
starvation from a high calorie-low carbohydrate diet.  
Fasting and a ketogenic diet share many metabolic features. Therefore, we 
assessed the gene expression signature of Cpt2lox/lox and Cpt2L-/- mice fed a ketogenic diet  
for 6 days. Consistent with the microarray data from 24hr fasting liver, the livers from 
Cpt2L-/- mice exhibited a dramatic increases in Pparα target gene expression compared to 
control mice (~170-fold increase in Pdk4, >50-fold increase in Elovl7) (Table 4-1). Also, 
oxidative gene expression in the livers of Cpt2L-/- mice was increased in ketogenic diet-
fed mice (Figure 4-8F). Gluconeogenic gene expression, serum insulin and oxidative 
gene expression in the kidney, gastrocnemius muscle, and heart were also consistent with 
the fasting data (Figure 4-9). Finally, we measured the gene expression (Table 4-1) and 
serum concentrations of the secreted hepatokines Fgf21, Gdf15 and Igfbp1 (Figure 4-




Figure 4-8. A ketogenic diet results in hypoglycemia, a depletion of adipose triglyceride and 
eventually lethality in Cpt2L-/- mice. 
(A) Body weights of Cpt2lox/lox and Cpt2L-/- mice fed a normal chow or ketogenic diet for 6 days 
(normal chow, n=6-10; ketogenic diet, n=5-6).  
(B) Wet weight of liver from Cpt2lox/lox and Cpt2L-/- mice fed a ketogenic diet for 6 days (n=5-6). 
(C) Liver damage measured by serum ALT activity of Cpt2lox/lox and Cpt2L-/- mice fed a ketogenic diet 
(n=5). 
(D) Serum metabolites in Cpt2lox/lox and Cpt2L-/- mice after a 6-day ketogenic diet (n=5-6). 
(E) Gross morphology of Cpt2lox/lox and Cpt2L-/- mice fed a ketogenic diet.  
(F) Gene expression of fatty acid oxidation genes in the liver of Cpt2lox/lox and Cpt2L-/- mice fed a 
ketogenic diet (n=6). 
(G) Serum concentrations of Fgf21, Gdf15 and Igfbp1 of Cpt2lox/lox and Cpt2L-/- mice fed a ketogenic 
diet (n=6). 
(H) Validation of results of microarray by qRTPCR in liver of Cpt2lox/lox and Cpt2L-/- mice fed a 
ketogenic diet (n=6). 
(I) Gene expression of fatty acid oxidation genes in the liver of Cpt2lox/lox and Cpt2L-/- mice fed a 
ketogenic diet (n=6). 
(J) Serum concentrations of Fgf21, Gdf15 and Igfbp1 of Cpt2lox/lox and Cpt2L-/- mice fed a ketogenic 
diet (n=6). 




Figure 4-9.  A ketogenic diet results in compensation from kidney, gastrocnemius muscle and heart. 
(A) Gene expression of gluconeogenic genes Pck1, Pck2, and G6pase in liver of Cpt2lox/lox and Cpt2L-
/- mice fed a ketogenic diet (n=6). 
(B)  Gene expression of gluconeogenic genes Pck1, Pck2, and G6pase in kidney of Cpt2lox/lox and 
Cpt2L-/- mice fed a ketogenic diet (n=6). 
(C) Serum concentrations of insulin in Cpt2lox/lox and Cpt2L-/- mice fed a ketogenic diet (n=5-7). 
(D) Gene expression of fatty acid oxidation genes in kidney of Cpt2lox/lox and Cpt2L-/- mice fed a 
ketogenic diet (n=6). 
(E) Gene expression of fatty acid oxidation genes in gastrocnemius muscle of Cpt2lox/lox and Cpt2L-/- 
mice fed a ketogenic diet (n=6). 
(F) Gene expression of fatty acid oxidation genes in heart of Cpt2lox/lox and Cpt2L-/- mice fed a 
ketogenic diet (n=6). 
Data are expressed as mean ± SEM. *p<0.05; **p<0.01; ***p<0.001. 
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control Cpt2lox/lox mice, Cpt2L-/- mice further exacerbated this increase in serum 
hepatokines. These data show that the ketogenic diet elicits a similar yet further 
exacerbated physiologic program in Cpt2L-/- mice compared to fasting. 
To better determine the kinetics of the ketogenic-induced weight loss and 
hypoglycemia in mice deficient in hepatic fatty acid β-oxidation, we again placed 
Cpt2lox/lox and Cpt2L-/- mice on a ketogenic diet and measured their body weights and 
blood glucose daily over 4 days.  Cpt2lox/lox and Cpt2L-/- mice had no significant 
differences in fed blood glucose (Figure 4-10A) or body weight (Figure 4-10B) over 
these 4 days although by day 4, Cpt2L-/- mice had accelerated body weight loss.  This 
indicates that a lack of systemic gluconeogenesis was not the primary cause of lethality in 
Cpt2L-/- mice.   
To determine the systemic metabolic effects of a loss of hepatic Cpt2, we 
measured blood and tissue acylcarnitines in Cpt2lox/lox and Cpt2L-/- mice before and over 
the 4-day ketogenic diet challenge.  As the liver is a major site of carnitine biosynthesis, 
there were no changes in free carnitine in the liver; however, there was a significant 
suppression in free carnitine in the blood of Cpt2L-/- mice, indicating a systemic 
deficiency (Figure 4-10C). Total acylcarnitines and short chain acylcarnitines were 
significantly suppressed in both chow and ketogenic diet fed blood of Cpt2L-/- mice 
(Figure 4-10D, Table 4-2).  However, the substrates specific for Cpt2, long chain 
acylcarnitines, showed a progressive increase in blood over time, indicating increased 
hepatic excursion of long chain acylcarnitines in Cpt2L-/- mice (Figure 4-10E, Table 4-2).  
Finally, we measured liver acylcarnitines in chow fed and 4-day ketogenic diet fed mice.  




Figure 4-10. Time course of body weight, blood glucose and acylcarnitines in Cpt2L-/- mice fed a 
ketogenic diet. 
(A) Blood glucose of Cpt2lox/lox and Cpt2L-/- mice during a 4-day ketogenic diet (n=5). 
(B) Body weight of Cpt2lox/lox and Cpt2L-/- mice during a 4-day ketogenic diet (n=5). 
(C) Liver and blood L-carnitine of Cpt2lox/lox and Cpt2L-/- mice following a 4-day ketogenic diet (n=5). 
(D) Total blood acylcarnitines and acetylcarnitine of Cpt2lox/lox and Cpt2L-/- mice following a 4-day 
ketogenic diet (n=5). 
(E) Daily blood long chain (C18:0, C18:1) acylcarnitines of Cpt2lox/lox and Cpt2L-/- mice during a 4-day 
ketogenic diet (n=5). 
(F) Total liver acylcarnitines and acetylcarnitine of Cpt2lox/lox and Cpt2L-/- mice following a 4-day 
ketogenic diet (n=4-5). 
(G) Total liver long chain (C16:0, C18:0, C18:1) acylcarnitines and acetylcarnitine of Cpt2lox/lox and 
Cpt2L-/- mice following a 4-day ketogenic diet (n=4-5). 
Data are expressed as mean ± SEM. *p<0.05; **p<0.01; ***p<0.001.  
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liver acetylcarnitine that was exacerbated by the ketogenic diet (Figure 4-10F), and an 
increase in long chain acylcarnitines even in chow fed mice (Figure 4-10G, Table 4-3).  
These data show that a loss of hepatic fatty acid β-oxidation results in an accelerated 
depletion of adipose lipid stores and increased peripheral catabolism following fasting or 
a ketogenic diet that is ultimately unsustainable. 
Discussion 
The importance of fatty acid β-oxidation is made evident by multiple inborn 
errors in this pathway that cause serious human disease (28, 83, 84).  For example, 
hypomorphic mutations in CPT2 result in metabolic disease of increasing severity.  The 
most severe form presents as hypothermia, cardiomegaly, hepatomegaly and 
hypoglycemia in the first days of life from the important roles of fatty acid β-oxidation in 
adipocytes, heart and liver.  Additionally, hypomorphic mutations in CPT1a result in 
hypoketotic-hypoglycemia (54) and a loss of CPT1a or CPT1b in mice is early 
embryonic lethal (29, 30). Given that the liver is critical for the adaptation to fasting and 
fatty acid β-oxidation is central to this response, we asked what the requirements of 
hepatic fatty acid β-oxidation are in vivo.  Surprisingly, we found that mice with a 
hepatocyte-specific deletion of mitochondrial long chain fatty acid β-oxidation not only 
survived the perinatal period but also survived a 24hr fast with normal blood glucose but 
a lack of ketone bodies. Perhaps not surprisingly, survival during food deprivation has 
been so evolutionarily important that multiple compensatory systems are in place for such 
a critical adaptation. 
While blood glucose is maintained within a tight range, ketones can change 
dramatically from micromolar to millimolar concentrations (53).  Our data suggests that 
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the liver produces almost all of the circulating ketones.  The total loss of ketone 
utilization via KO of Oxct1 results in perinatal lethality in mice (56).  Therefore we 
speculate that local ketone production (e.g. within the CNS) or a small amount of fatty 
acid independent ketogenesis may enable the survival of Cpt2L-/- mice during the 
perinatal period, a time of robust ketolysis (85, 86).  Several effects of βHB indirectly 
associated with its metabolic role have been suggested (87). βHB is an endogenous ligand 
for at least two Gi/o-coupled GPCRs, HCAR2 and FFAR3, that suppress adipose lipolysis 
and sympathetic activity respectively (88, 89).  Given the dramatic peripheral catabolism 
in ketogenic diet fed Cpt2L-/- mice that have suppressed circulating βHB, these 
nonmetabolic roles of ketones likely play a significant role in regulating systemic 
physiology during food deprivation. The inability to affect these two receptors would 
lead to enhanced fasting lipolysis consistent with Cpt2L-/- mice.  Therefore, βHB is likely 
critical for restraining lipolysis, particularly under conditions where insulin is low.  
Pparα has been postulated to be activated by fatty acid derived ligands.  Some 
ligands are thought to be derived from de novo fatty acid synthesis (90-92), however that 
seems to be an unlikely driver of fasting gene expression in Cpt2L-/- mice.  Alternatively, 
triglyceride hydrolysis has been shown to be critical for Pparα directed transcription.  The 
loss of Atgl, the rate setting step in triglyceride hydrolysis, results in a loss of Pparα 
transcription presumably from the loss of an endogenous Pparα ligand produced upon 
hydrolysis (93-96). It will be interesting to determine if lipids derived from lipid droplet 
triglyceride hydrolysis are required for the increased Pparα mediated transcription in 
Cpt2L-/- mice or alternatively, if exogenous lipid uptake can directly activate Pparα target 
genes independent of lipid droplets. 
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One robust transcriptional target of Pparα is the hepatokine Fgf21 (74, 75).  
Although it is expressed in several tissues, most of the circulating Fgf21 is derived from 
hepatocytes (97).  Fgf21 is induced by fasting and ketogenic feeding in rodents and acts 
largely to increase energy expenditure via an autocrine and endocrine manner (79).  
Fgf21 is emerging as a potential therapeutic for obesity and insulin resistance by 
increasing glucose uptake in adipocytes and increasing energy expenditure.  The robust 
increase in circulating Fgf21 in Cpt2L-/- mice suggests that it provides some of the signal 
required to increase systemic catabolism to maintain energy homeostasis although Gdf15 
and Igfbp1 likely also contribute. Consistent with Cpt2L-/- mice, humans with 
mitochondrial disease exhibit increased circulating FGF21 (98).  The loss of the anti-
catabolic βHB and the gain of procatabolic hepatokines such as Fgf21, Gdf15 and Igfbp1, 
likely all contribute to the exaggerated lipolysis seen in Cpt2L-/- mice upon fasting or 
ketogenic feeding, and mitigate hepatic energy expenditure defects in mice without the 
capacity for long chain mitochondrial fatty acid β-oxidation. 
It is clear that the liver plays an important role in regulating systemic metabolism, 
and that hepatic fatty acid β-oxidation represents an important component, particularly 
when carbohydrate intake is limiting.  However, our data shows that there is an incredible 
systemic adaptation mediated by the liver to regulate extra-hepatic metabolism to ensure 
survival.  These data highlight the need to better understand the tissue-specific 
contributions of macronutrient metabolism to gain insight into the regulation of 
integrative metabolic physiology.  
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Table 4-2. Daily blood acylcarnitine profile of Cpt2lox/lox and Cpt2L-/- mice fed a chow diet then a 




Table 4-3. Liver acylcarnitine profile of Cpt2lox/lox and Cpt2L-/- mice fed a chow diet or a ketogenic 
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CHAPTER 5. Metabolomic profiling reveals a role for CPT1c in 




Although the mammalian brain is lipid rich and mutations in lipid metabolizing 
enzymes result in debilitating neurological disease, neurons are generally not thought to 
rely on mitochondrial fatty acid beta-oxidation for bioenergetic requirements. Neurons 
instead mainly utilize the oxidation of glucose for most of their bioenergetics needs, 
although, during prolonged fasting, ketone bodies (i.e. acetoacetate and beta 
hydroxybutyrate) can also be used (60). Most neurons have a low amount of the rate-
setting enzymes in mitochondrial long chain fatty acid catabolism, namely, the malonyl-
CoA sensitive Carnitine Palmitoyltransferase 1 (CPT1a and CPT1b) enzymes which limit 
most neurons potential for mitochondrial fatty acid beta-oxidation (146). 
Carnitine acyltransferases are enzymes that catalyze the exchange of acyl groups 
between carnitine and Coenzyme A (CoA) to facilitate the transport acyl chains between 
the cytoplasm to the mitochondrial matrix (147). CPT1 isoenzymes (EC 2.3.1.21) 
preferentially are positioned on the outer mitochondrial membrane and transfer long 
chain acyl groups from CoA to carnitine. CPT1a and CPT1b are malonyl-CoA sensitive 
and therefore inhibited when malonyl-CoA levels are high (e.g. during high glucose 
flux). The malonyl-CoA insensitive CPT2, on the other hand, is located in the 
mitochondrial matrix and reversibly transfers the acyl chain back to CoA to facilitate 
beta-oxidation. Although neurons have a relative dearth of CPT1a and CPT1b [2], they 
express a CPT1 homologue, CPT1c (148).  
CPT1c has a high primary amino acid sequence similarity and identity to the 
canonical CPT enzymes. Therefore, it was surprising that definitive acyltransferase 
activity or enhanced oxidation of fatty acids could not be shown for CPT1c (148-150). 
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CPT1c KO mice exhibit both behavioral and metabolic deficits (150-153). Over-
expression of CPT1c in the brain of developing transgenic mice results in 
microencephaly (70). Therefore, it is clear that CPT1c plays an important role in brain 
function. Although there were several metabolites identified that have been altered after 
over-expression (70, 154) or knockout of CPT1c (151), the reaction that CPT1c catalyzes 
has remained elusive. 
Here we used an unbiased metabolomic approach to broadly understand the 
consequence of CPT1c deletion to gain insight into the biochemical and physiological 
roles of CPT1c function. Similar to previous work in heterologous systems, we did not 
see changes consistent with a role for CPT1c in long chain fatty acid beta oxidation. 
However, there were changes in several fatty acid derived metabolites including 
endocannabinoids, which may explain the suppressed food intake in these models. Also, 
some of the most abundant changes were in redox biochemistry consistent with several 
models of CPT1c function recently proposed. 
Experimental Procedures 
Animals 
Mice with a targeted knockout of exons 1 and 2 of the cpt1c gene were propagated and 
genotyped as previously described (149, 150). Mice were fed a standard lab chow 
(Harlan 2018) after weaning. All procedures were performed in accordance with the 
National Institutes of Health Guide for the Care and Use of Laboratory Animals and 
under the approval of the Johns Hopkins Medical School Animal Care and Use 
Committee. 
Western blot analysis 
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A polyclonal rabbit antibody against CPT1c was used as a primary antibody for CPT1c 
detection in WT and CPT1c KO mice (149, 150). Anti-rabbit horseradish peroxidase 
(HRP) was used as a secondary antibody, and the blots for CPT1c were developed using 
ECL reagent. Mouse monoclonal anti-HSC70 (Santa Cruz biotech) and mouse 
monoclonal anti beta-actin (Sigma) was used as primary antibodies for loading control. 
Cy3 conjugated fluorescent secondary antibody was used for both HSC70 and beta-actin 
antibodies. 
Metabolomic measurements and profiling 
Unbiased metabolomics analysis of whole brain samples from WT and CPT1c KO mice 
(n=8/group) that were fasted overnight was performed using liquid chromatography/ 
tandem mass spectrometry (HPLC/MS/MS2) and gas chromatography/mass spectrometry 
(GC/MS) platforms. The platform was able to screen and identify several metabolites in 
multiple classes, such as amino acids, lipids, and nucleotides. A complete list of the 
metabolites identified in this study is given in Tables 6-1, 6-2, 6-3 and 6-4. General 
platform methods about metabolomics measurements and profiling are described in the 
metabolomics study done by Eckel-Mahan et al. (155) 
Statistical analysis 
Pair-wise comparisons between CPT1c WT and KO were performed using 
Welch’ s two-sample t-tests. From the p -values, any value below the significance level 
of 0.05 was interpreted as statistically significant. 
Results 
Carnitine Palmitoyltransferase-1c KO mice 
Although CPT1c is widely expressed in transformed cells and tumors (156), we  
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Figure 5-1. CPT1c KO mice and metabolomics profiling. 
(A) CPT1c protein from homogenized brains of WT and CPT1c KO mice were analyzed by western 
blot using the anti-CPT1c antibody. Hsc70 and Actin were used for loading controls. 
(B) A schematic pathway of metabolomics profiling for KO and WT brains. A commercial supplier of 
metabolic analysis homogenized 8 brain samples from independent mice to extract organic 




have only been able to reliably detect CPT1c in neurons in vivo.  To understand the 
endogenous function of CPT1c, we performed metabolomics profiling on brains of 
CPT1c KO mice and their littermate controls. Therefore, we collected and snap froze the 
brains of CPT1c KO and WT littermate sex matched adult mice after an overnight fast. 
Western blot analysis of WT and CPT1c KO mice showed that KO mice were indeed 
completely deficient of CPT1c (Figure 5-1A). These samples were then homogenized 
and the small organic metabolites were extracted and analyzed by a mixture of GC-MS 
and LC-MS/MS by a commercial supplier of metabolomic analyses (Figure 5-1B). 
Below, we detail the changes in steady-state biochemical between WT and KO brains 
that were identified through an unbiased metabolomic screen.  
Fatty acid oxidative metabolites show no difference in overall trend in CPT1c KO mice 
Given the high primary amino acid homology of CPT1c to other CPTs, it would 
follow that CPT1c may be involved in fatty acid beta oxidation or at least in long chain 
acyl-CoA metabolism. If CPT1c was involved in fatty acid oxidation, we would expect 
that the deletion of CPT1c would decrease the level of acyl-carnitines and potentially 
increase the levels of other long chain acyl-CoA dependent biosyntheses. A broad range 
of lipid species were identified in the metabolomic screen (Table 5-1). No changes were 
seen in oleoyl-carnitine, beta-hydroxybutyrate, or acetyl-carnitine, as we would have 
expected (Figure 5-2A). However, the metabolomics analysis did show that free 





Figure 5-2. Loss of CPT1c results in decreased free carnitine and no change in fatty acid oxidative 
metabolites in the brain. 
(A) Biochemicals involved in carnitine, amino acid and fatty acid metabolism from WT and CPT1c 
KO brains were compared through metabolomics analyses, revealing a statistically significant 
change in levels of free carnitine (p=0.084), 3-dehydrocarnitine (p=0.0103), glutaroylcarnitine 
(p=0.0244) and betaine (p=0.0383). 
(B) Schematic of biochemical pathways altered in CPT1c KO mice. Based on this schematic 
pathway, glutaroyl carnitine and betaine may affect the level of free carnitine, since these 




Figure 5-3. Loss of CPT1c results in decreased endocannabinoids in the brain. 
(A) Biochemicals involved in fatty acid biochemistry from WT and CPT1c KO mouse brains were 
compared to determine if metabolomics analyses showed any statistically significant changes. 
There was an overall decreasing trend in endocannabinoids in CPT1c KO mice. Specifically, 
eicosapentaenoate (p=0.0236) and palmitoylethanolamine (p=0.0331) significantly decreased in 
CPT1c KO mice.  
(B) A schematic of how a decrease in endocannabinoids can induce a decrease in food intake by 
interacting with CB1 and CB2 cannabinoid receptors. 
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Among the metabolites that showed a statistically significant difference, only 3-
dehydrocarnitine increased in CPT1c KO mice while glutaroyl carnitine, betaine and free 
carnitine decreased. Glutaroyl carnitine and betaine are biochemicals that are involved in 
carnitine biosynthesis (Figure 5-2B; Table 5-2). Glutaroyl carnitine is involved in lysine 
metabolism, which is one of the amino acids that is used to synthesize carnitine. In the 
carnitine biosynthesis pathway, betaine takes the form of butyrobetaine to synthesize L-
carnitine (157). As a result, it is possible that the decrease in glutaroyl carnitine and 
betaine could have caused free carnitine levels to decrease in CPT1c KO mice. Previous 
studies also tested hypothalamic and cortical explants from WT and CPT1c KO mice for 
their ability to oxidize fatty acids, but there was no evidence that unique properties in 
neurons existed to allow activation of fatty acid oxidation by CPT1c (149). CPT1c over-
expressed in heterologous cells in vitro also did not show a change in fatty acid oxidation 
(149). Therefore, our results remain consistent with previous findings that CPT1c, 
although it is highly homologous with its isoforms CPT1a and CPT1b, does not 
participate substantially in neuronal mitochondrial fatty acid oxidation. 
Loss of CPT1c results in decreased levels of endogenous endocannabinoids 
Several studies have investigated the neurological role of endocannabinoids on 
food intake (158). A study investigated the role of endocannabinoids in regulating food 
intake in the tongue, gut and different brain regions, suggesting that the cannabinoid 
system plays a role in modulating the activity of neural pathways that regulate food 
intake and energy expenditure (158). The brain cannabinoid system, as shown in Figure 




Figure 5-4. Loss of CPT1c results in elevated oxidative demands in the brain. 
(A) In a comparison of biochemical involved in redox homeostasis in WT and CPT1c KO mouse 
brains, GSSG and 5-oxoproline were statistically significant. GSSG levels increased in CPT1c 
KO mice with a p-value of 0.0307, while 5-oxoproline decreased in KO mice (p=0.0291). The 
biochemical shown displayed an overall increasing trend in CPT1c KO mice. 
(B) A schematic of the gamma-glutamyl redox cycle. Based on the pathway, an increase in the 
biochemical from Fig 4A may cause the cells to become more sensitive to oxidative stress.  
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cannabinoid receptors. From our metabolomics analyses, there was a significant decrease 
in palmitoylethanolamine and a trend for a decrease in 2-oleolylglycerol in CPT1c KO 
mouse brains compared to WT mouse brains (Figure 5-3). There was no significant 
difference between WT and CPT1c KO mice for free nonesterified fatty acids (Table 5-
1). Among the metabolites shown in Figure 5-3A, eicosapentaenoate and 
palmitoylethanolamine showed a significant decrease in CPT1c KO mice with a p-value 
of 0.0236 and 0.0331, respectively. There was also a slight increase in ethanolamine 
between WT and CPT1c KO mice, and decrease in 2-oleoylglycerol (p=0.0769), an 
endogenous cannabinoid (CB) CB-1 agonist (Figure 5-3A). 
Loss of CPT1c results in increased levels of glutathione 
The oxidized form of GSH (GSSG) and 5-oxoproline, biochemicals involved in 
the gamma-glutamyl redox cycle, resulted in a statistically significant difference in 
CPT1c KO mice (Table 5-2). GSSG and cysteineglutathione disulfide levels increased 
while 5-oxoproline levels decreased in CPT1c KO mice (Figure 5-4A). Based on the 
schematic redox pathway shown in Figure 5-4B, our results suggest that CPT1c may 
play a role in oxidative metabolism. This is consistent with findings in cancer 
metabolism. Zaugg et al. depleted the levels of CPT1c in MCF-7 cells to determine 
whether these cells were sensitive to oxidative stress. Hypoxia was used as a stress 
inducer, and they found that CPT1c depletion caused an increased sensitivity to oxidative 
stress, implying that CPT1c may play a crucial role in protecting the cells from stress 
from the environment (156). Furthermore, the loss of CPT1c resulted in an increase in 
ceramides (151, 152), a key mediator of oxidative stress (159, 160). However, the 
mechanism and role of CPT1c in oxidative metabolism remains unknown. 
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Discussion 
Role of CPT1c in behavior and physiology 
Carnitine acyltransferases are enzymes that catalyze the exchange of acyl groups 
between carnitine and CoA to facilitate the transport of acyl groups from the cytoplasm to 
the mitochondrial matrix. Carnitine acetyltransferase (CRAT) and carnitine 
octonyltransferase (CROT) facilitate transport short- and medium-chain acyl-CoA, while 
CPT1 facilitate transports long chain acyl-CoA to the mitochondria. CPT1 enzymes are 
encoded by three genes in mammals that are localized in different tissues and have 
different properties. CPT1a, which is enriched in the liver, has been heavily studied due 
to its crucial role in β -oxidation and human fatty oxidation disorders (OMIM #255120) 
and is lethal when knocked out in mice (28). CPT1b is localized mainly in the muscle and 
is a regulator for the use of fatty acids in muscle and is also lethal when knocked out in 
mice (27). These two enzymes, which are present on the outer mitochondrial membrane, 
play a critical role in regulating and facilitating fatty acid beta-oxidation.  
The brain specific CPT1c is highly homologous to its closely related genes, 
CPT1a and CPT1b (148). However, despite its high homology, CPT1c does not catalyze 
acyl transfer from long chain acyl-CoA to carnitine (148-150). Other distinguishing 
properties of CPT1c include a longer C-terminus and localization in the endoplasmic 
reticulum (ER) instead of the mitochondria (154). Although it does not facilitate acyl 
transfer in the cell, CPT1c most likely remains sensitive to the endogenous allosteric 
CPT1 inhibitor, malonyl-CoA, binding with a similar affinity as CPT1a (148, 150). 
Moreover, while other isoenzymes are expressed in a broad range of organisms, CPT1c 
seems to have risen late in evolution, raising the question whether CPT1c has a specific 
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role in mammalian brain function. 
Several studies used CPT1c knockout (KO) and CPT1c transgenic mice to 
investigate the role of CPT1c in the CNS. Knockout studies showed that loss of CPT1c 
did not affect the viability or fertility of the mice, but resulted in a suppression in food 
intake and decrease in body weight when they were fed a normal or low-fat diet (150, 
153). Paradoxically, when high fat diet was given to CPT1c KO mice, they exhibited 
diet-induced obesity, which ultimately resulted in a diabetic phenotype (149, 150). Even 
though fatty acid oxidative metabolites showed no significant change based on the 
metabolomic analysis, due to a decrease in peripheral energy expenditure CPT1c KO 
mice were more susceptible to obesity and diabetes when fed a high fat diet. This 
suggests that CPT1c has a hypothalamic function in protecting the body from adverse 
weight gain when the mice were fed a high fat diet. Transgenic CPT1c mice (CPT1c-
TgN), on the other hand, which allowed conditional expression of CPT1c in a tissue-
specific manner via cre-lox recombination, showed enhanced expression of CPT1c and 
they were protected from diet-induced obesity even on a high-fat diet (70). 
CPT1c KO mice also showed impaired spatial learning (151). Cpt1c deficiency 
was shown to alter dendritic spine morphology by increasing immature filopodia and 
reducing mature mushroom and stubby spines. Compared to WT mice, CPT1c KO mice 
showed a higher escape latency, implying that they had a delay in the acquisition phase 
(151). Based on this study, CPT1c deficiency interfered with consolidating new 
information but did not affect retaining information or motor behavior. As a result, there 
may be other physiological roles of CPT1c in addition to regulating food intake and 
energy expenditure consistent with its broad expression throughout the nervous system 
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(151). 
Endocannabinoid regulation of food intake 
Endocannabinoids are endogenous ligands that bind to cannabinoid receptors to 
regulate many aspects of physiology and behavior. Specifically, the brain 
endocannabinoid system regulates food intake via the hypothalamus, where it activates 
necessary mediators to induce appetite after a short-term food deprivation. CB1 receptor 
KO mice showed reduced food intake, similar to CPT1c KO mice (161, 162). Based on 
our results, CPT1c could be interacting with the cannabinoid system, causing an overall 
decreasing trend in endocannabinoids in CPT1c KO mice. In this context, the loss of 
CPT1c could have influenced the endocannabinoid system and its function to regulate 
food intake and body weight, which may explain the suppressed food intake in CPT1c 
KO mice (149, 153). Therefore, a decrease in endocannabinoids based on metabolomic 
profiling may suggest a putative role of the endocannabinoid system in suppressing food 
intake in CPT1c KO mice. However, it is unclear if CPT1c affects endocannabinoid 
metabolism directly or more likely indirectly by altering neuronal specific fatty acid 
metabolism. 
Glutathione and redox metabolism 
Neurons are particularly sensitive to oxidative stress and damage caused by 
reactive oxygen species (ROS). On the cellular level, there are many endogenous 
metabolic stress inducers, such as ROS produced from the mitochondria and cytosolic 
enzymes, such as cyclooxygenase and lipoxygenase. There are also various exogenous 
conditions that can also promote the level of ROS species to increase, such as H2O2 and 
hypoxia, that induces irreversible cellular damage or cell death. As shown by the pathway 
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in Figure 5-4B, reduced glutathione (GSH) and oxidized glutathione (GSSG) are tightly 
regulated in order to maintain cellular redox homeostasis and to protect the cells from 
oxidative damage (160). Carrasco et al. showed that CPT1c expression correlated with 
ceramide production and loss of CPT1c resulted in reduced ceramide levels. (151). A 
recent study on the role of CPT1c in cancer cells in response to metabolic stress showed 
that CPT1c could participate in protecting cells from stress. In addition, they postulated 
that metabolic stress could alter regulation of the CPT1c gene, reducing ATP production 
and increasing sensitivity towards metabolic stress (156). Here, we showed that CPT1c 
deficiency results in an increased oxidative environment. This may indicate that although 
CPT1c does not contribute in large part to beta-oxidation, it may be involved in other 
neuron specific oxidative metabolism. Alternatively, CPT1c may need to be activated in a 
yet to identified stress-induced manner. Barger et al. (163) showed that CPT1c was 
required for leukemia growth under low glucose conditions. Therefore, CPT1c may have 
a context dependent role in fatty acid catabolism. Although here we show that CPT1c 
could play a role in oxidative stress, the precise role of CPT1c in relation to oxidative 













Table 5-3. Biochemicals from the carbohydrate and energy pathways  
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Table 5-4. Biochemicals in nucleotide, cofactors and vitamins, and xenobiotic pathways 
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TISSUE SPECIFIC ROLES OF 
FATTY ACID OXIDATION 
 
 




Through this thesis, a conditional knockout of Cpt2 has allowed us to understand 
the role of fatty acid oxidation in vivo. It has long been suggested that mitochondrial 
dysfunction and suppressed BAT or WAT fatty acid oxidation contributes to changes in 
body weight and glucose tolerance. Some strategies to reverse obesity include increasing 
adipose energy expenditure to improve systemic obesity-related complications. However, 
through the adipocyte-specific deletion of Cpt2 mouse model, I found that although 
adipocyte fatty acid oxidation was an important metabolic process for environmental and 
nutritional homeostasis, it did not alter body weight or improve glucose tolerance.  
In BAT, fatty acid oxidation was crucial for acute adaptation to cold by providing 
energy required for heat generation and transcriptional regulation of BAT thermogenesis. 
Although Cpt2A-/- mice were unable to maintain their body temperature in the cold, they 
were able to maintain energy homeostasis via alternative mechanisms during moderate 
environmental challenges. Due to the large potential to alter energy expenditure, it is 
tempting to suggest that defects in brown or beige adipocytes can lead to an obesogenic 
phenotype at thermoneutrality. However, my studies have shown that incompetent BAT 
does not potentiate obesity, even at thermoneutrality. Surprisingly, fatty acid oxidation 
was required to maintain the identity and morphology of BAT. This suggests that 
adipocyte fatty acid oxidation plays a major role in mediating and regulating molecular, 
cellular and physiological adaptations to maintain body temperature and energy 
homeostasis.  
The molecular mechanisms by which high fat diets contribute to metabolic 
pathologies are not well understood, but several themes have emerged. Implicated in the 
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etiology and progression of obesity-related pathologies is oxidative stress, ER stress and 
inflammation originating locally at adipose depots but acting systemically to promote 
insulin resistance. Hence, it has been suggested that preventing local adipose tissue 
inflammation may have beneficial systemic effects against insulin resistance. In contrast, 
the loss of fatty acid oxidation in BAT and WAT suppressed oxidative stress and 
inflammation upon a high-fat diet feeding, but it did not improve systemic insulin 
resistance. Furthermore, the loss of fatty acid oxidation in adipose tissue did not alter 
body weight in varying environmental conditions when mice were either fed a high fat or 
low fat diet.  
In the liver, fatty acid oxidation is crucial to maintain energy homeostasis upon 
prolonged fasting via gluconeogenesis or ketogenesis. In fact, gluconeogenesis is 
predominantly carried out in the liver with minor contributions from the kidney and gut. 
In the hepatocyte-specific deletion of Cpt2 mouse model, it is clear that the liver plays an 
important role in regulating systemic metabolism, especially when carbohydrate intake is 
limiting. However, my studies indicate that in the absence of fatty acid oxidation in the 
liver, the kidney is capable of maintaining glucose homeostasis. Additionally, the liver 
was able to mediate systemic adaptations, such as increase catabolism through circulating 
hepatokine Fgf21, to maintain energy homeostasis and ensure survival during prolonged 
fasting. However, when carbohydrate intake was limited through a ketogenic diet, Cpt2L-
/- mice were not able to survive upon a heavy lipid burden. Overall, the control of energy 
expenditure represents a critical evolutionarily conserved survival mechanism that is 
likely regulated by multiple overlapping and compensatory systems, which may present a 





What would be the physiological, molecular and biochemical response when Cpt2L-/- 
mice are put on a 60% high fat diet? 
Studying the role of fatty acid oxidation in the liver has opened a whole new field 
of research in understanding how the liver regulates alternative mechanisms to maintain 
energy homeostasis and ensure survival in the absence of fatty acid oxidation. In my 
initial studies, I have shown that other tissues were able to contribute to maintain glucose 
and energy homeostasis during prolonged fasting (24hr fast) via increasing systemic 
catabolism via Pparα-regulated hepatokines Fgf21, Gdf15 and Igfbp1 under a standard 
chow diet. Therefore, it would be interesting to see if the same physiological and 
molecular effects take place upon a high fat diet feeding.  
Preliminary data have shown that male and female Cpt2L-/- mice are resistant to 
body weight gain upon a 60% high-fat diet feeding and had significantly less fat mass 
than Cpt2lox/lox control mice. It would be important to determine which metabolic factor is 
preventing Cpt2L-/- mice from gaining weight. Is it Fgf21 or Atgl that is increasing 
lipolysis in adipose depots to maintain energy homeostasis? Also, by performing qRT-
PCR, we can also investigate the transcriptional response of these mice on a high fat diet. 
What changes would we see in Pparα regulated genes? Would they have more severe 
hepatomegaly than 24hr fasted mice? Would these mice still be able to maintain energy 
homeostasis? It would also be helpful to generate Cpt2 and Fgf21 or Cpt2 and Atgl liver-
specific double knockout mouse models and repeat the same experiments to see if we can 
rescue any of the phenotypes previously seen. Furthermore, using these double knockout 
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mouse models, we can investigate if systemic catabolism is still increased during fed, 
24hr fasted and high fat diet conditions. 
What is the effect of Cpt2 on insulin sensitivity and insulin signaling? 
Consistent with my initial studies presented in chapter 4, Cpt2L-/- mice on a 60% 
high fat diet for 16 weeks had suppressed circulating β-hydroxybutyrate and insulin, but, 
surprisingly, had normal levels of glucose. Additionally, Cpt2L-/- mice had improved 
glucose tolerance and insulin sensitivity compared to control mice when these two 
tolerance tests were administered before the body weights of control and Cpt2L-/- mice 
were different. Insulin signaling in the liver is mediated via the hepatic insulin receptor 
and downstream kinases (164). Furthermore, Akt is known to affect the mTorc1 pathway 
and insulin-induced de novo lipogenesis (164). Therefore, performing an acute insulin 
stimulation to look at the insulin receptor and downstream targets in the insulin signaling 
pathway would be important to understand the role of hepatic fatty acid oxidation and its 
regulation in insulin release and glucose homeostasis. Additionally, since we saw a huge 
suppression in insulin, using radiolabeled substrates to perform an in vivo lipogenesis 
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